Inventa Scoring System: A Strategic Framework for Prioritizing Natural Extracts in Drug Discovery

Abstract

This article introduces and details the Inventa scoring system, a multi-faceted framework designed to systematically evaluate and prioritize natural extracts for drug development. Aimed at researchers and pharmaceutical professionals, we first explore the core challenge of navigating the vast 'natural product library' and define Inventa's role. We then break down its methodological pillars—bioactivity, chemical diversity, ADMET properties, and scalability—providing a step-by-step application guide. Common implementation hurdles and optimization strategies for scoring parameters are addressed. Finally, we validate Inventa against traditional selection methods and competing AI models, demonstrating its comparative advantage in improving hit rates and reducing early-stage attrition. The conclusion synthesizes how Inventa transforms natural product screening from an art into a data-driven science.

Beyond Serendipity: Why Systematic Scoring is Revolutionizing Natural Product Discovery

Within natural product drug discovery, the paradox lies between the theoretically infinite chemical diversity found in nature and the severe practical limitations of high-throughput screening (HTS) capacity and resource allocation. This Application Note details protocols and an analytical framework, grounded in the Inventa prioritization scoring thesis, designed to navigate this paradox by strategically focusing screening efforts on the most promising natural extracts.

Core Concepts & Quantifiable Data

The following table summarizes the key constraints defining the practical screening limits against estimates of global natural product diversity.

Table 1: The Scale of the Paradox – Diversity vs. Screening Capacity

Metric	Estimated Scale / Capacity	Key Implications for Screening
Estimated Total Microbial Species	1 trillion (10¹²)	Vast majority uncultured and chemically unexplored.
Estimated Plant Species	~450,000	Only a fraction (15-20%) phytochemically investigated.
Unique Natural Product Structures	>1,000,000 (reported)	Represents the "known" chemical space.
Theoretical Chemical Diversity	Effectively Infinite	Due to combinatorial biosynthesis, hybridization, and undiscovered taxa.
Practical HTS Capacity (Extracts/Year)	50,000 - 200,000	Limited by robotics, reagents, personnel, and cost.
Cost per HTS Campaign (Extract Library)	$50,000 - $500,000+	Significant financial constraint.
Hit Rate in Untargeted HTS	0.001% - 0.5%	Extremely low efficiency without prioritization.

The Inventa Scoring Framework for Prioritization

The Inventa thesis proposes a multi-parameter scoring system to rank natural extracts prior to biological screening. The composite score (S_Inventa) is calculated as: S_Inventa = (w₁ × S_Chemo) + (w₂ × S_Bio) + (w₃ × S_Source) Where w are weighting factors, and S are scores for Chemodiversity, Bio-relevant traits, and Source novelty.

Table 2: Inventa Scoring Parameters and Metrics

Parameter (Score)	Sub-Metrics (Examples)	Measurement Protocol	Weight (w) Range
Chemodiversity (SChemo)	LC-MS/MS Peak Count, Molecular Weight Distribution, NP-Likeness Score, Taxa-Specific Marker Ions	LC-HRMS/MS with Dereplication	0.3 - 0.5
Bio-Relevance (SBio)	Gene Cluster Presence (e.g., PKS, NRPS), Ethnobotanical Use, Ecological Defense Role	Genomic Mining / Literature Curation	0.3 - 0.4
Source Novelty & Viability (SSource)	Taxonomic Distinctiveness, Cultivation Yield, Sustainable Supply	16S/ITS Sequencing, Growth Curve Analysis	0.2 - 0.3

Detailed Experimental Protocols

Protocol 4.1: Rapid LC-HRMS/MS for Chemodiversity Scoring (SChemo)

Objective: Generate a chemical profile of an extract for dereplication and chemodiversity estimation. Materials: See "The Scientist's Toolkit" (Section 6). Procedure:

• Sample Prep: Reconstitute 1 mg of crude extract in 1 mL LC-MS grade MeOH. Centrifuge at 15,000g for 5 min.
• LC Conditions: Column: C18 (2.1 x 100 mm, 1.7 µm). Flow: 0.4 mL/min. Gradient: 5% to 100% MeCN in H₂O (0.1% Formic acid) over 18 min.
• HRMS/MS Analysis: Acquire full-scan MS data (m/z 150-2000) in positive and negative ionization modes. Data-Dependent Acquisition (DDA): Fragment top 10 ions per cycle.
• Data Processing: Use software (e.g., MZmine, GNPS) for peak picking, alignment, and adduct deconvolution.
• Dereplication: Query features (m/z, RT, MS/MS) against databases (GNPS, NP Atlas, Dictionary of Natural Products).
• Calculate S_Chemo:
  • Peak Richness: Normalized peak count (peaks per mg extract).
  • Novelty Score: 1 - (Number of dereplicated features / Total features).
  • NP-Likeness: Predict using a trained model (e.g., from COCONUT database).
  • Combine normalized sub-scores.

Protocol 4.2: Genomic DNA Extraction & PCR for Biosynthetic Gene Cluster (BGC) Screening

Objective: Detect presence of Polyketide Synthase (PKS) and Nonribosomal Peptide Synthetase (NRPS) gene fragments as a proxy for bio-relevance (S_Bio). Procedure:

• gDNA Extraction: From microbial biomass, use a kit (e.g., FastDNA Spin Kit). Elute in 50 µL TE buffer. Measure concentration via Nanodrop.
• Degenerate PCR: Set up 25 µL reactions: 20 ng gDNA, 1X PCR buffer, 2.5 mM MgCl₂, 0.2 mM dNTPs, 0.4 µM degenerate primers (e.g., K1F/M6R for KS domain), 1 U Taq polymerase.
• Thermocycling: Initial denaturation 95°C/5 min; 35 cycles of [95°C/30s, 48-55°C/30s, 72°C/1 min]; final extension 72°C/7 min.
• Analysis: Run PCR products on 1% agarose gel. A band ~700 bp (for KS domain) indicates potential PKS presence. Score as binary (present/absent) or semi-quantitative (band intensity).

Protocol 4.3: Taxonomic Identification for Source Novelty Score (SSource)

Objective: Determine taxonomic identity via 16S (bacteria) or ITS (fungi) sequencing. Procedure:

• PCR & Sequencing: Amplify 16S rRNA gene using primers 27F/1492R. Purify PCR product. Submit for Sanger sequencing.
• Sequence Analysis: Trim low-quality bases. BLASTn query against NCBI 16S rRNA database.
• Calculate Taxonomic Distinctiveness: Score based on phylogenetic distance to well-studied taxa in your library. A novel genus scores higher than a common Streptomyces.

Visualizations

Diagram 1: Inventa Prioritization Screening Workflow (76 chars)

Diagram 2: Core NRPS/PKS Biosynthetic Pathway (53 chars)

The Scientist's Toolkit

Table 3: Key Research Reagent Solutions for Featured Protocols

Item / Reagent	Function in Protocol	Example Product / Specification
LC-MS Grade Solvents	Ensure minimal ion suppression & background in HRMS.	Methanol, Acetonitrile, Water (0.1% Formic Acid).
UPLC C18 Column	High-resolution separation of complex natural extract metabolites.	2.1 x 100 mm, 1.7 µm particle size.
HRMS Calibration Solution	Accurate mass calibration for metabolite identification.	Sodium formate cluster or proprietary mix (e.g., from manufacturer).
Dereplication Database	Identify known compounds to focus on novelty.	GNPS, NP Atlas, in-house spectral library.
gDNA Extraction Kit	High-yield, pure genomic DNA from microbes/fungi.	FastDNA Spin Kit for Soil.
Degenerate PCR Primers	Amplify conserved domains of BGCs (PKS/NRPS).	K1F (TSGCSTGCTTGGAYGCSATC) / M6R (CGCAGGTTSCSGTACCAGTA).
DNA Polymerase for GC-Rich	Efficient amplification of high-GC% bacterial DNA.	Taq polymerase with 5x Q-Solution or similar.
PCR Purification Kit	Clean-up amplicons for sequencing.	Standard column-based kit.
Sanger Sequencing Service	Obtain sequence for taxonomic or BGC fragment ID.	Commercial provider (e.g., Eurofins).
Bioinformatics Pipeline	Process sequencing & MS data for scoring.	MZmine (MS), BLAST (Sequencing), R/Python for scoring.

Thesis Context: Prioritizing Natural Extracts for Drug Development

The identification of promising bioactive natural extracts from vast screening libraries presents a significant bottleneck in early-stage drug discovery. This Application Note details Inventa, a systematic Multi-Criteria Decision Analysis (MCDA) framework, developed as the core methodology of a doctoral thesis on rational natural extract prioritization. Inventa moves beyond single-parameter potency scoring, integrating quantitative data across multiple biological, chemical, and pharmacological axes to generate a unified Inventa Priority Score (IPS). This enables researchers to objectively rank extracts, optimize resource allocation, and accelerate the transition from hit to lead.

The Inventa MCDA Framework: Core Criteria & Data Integration

Inventa evaluates each extract against five weighted criteria, derived from a comprehensive literature review and expert elicitation. The standard weights are calibrated for early-stage anti-infective discovery but are modular.

Table 1: Inventa MCDA Core Criteria, Metrics, and Standard Weights

Criteria	Description	Key Quantitative Metrics	Standard Weight (%)
Efficacy (C1)	Primary biological activity.	IC50/EC50, % Inhibition at a standard concentration (e.g., 10 µg/mL), MIC.	35
Specificity & Safety (C2)	Selective toxicity versus host cells.	Selectivity Index (SI = CC50 / IC50), cytotoxicity (CC50) in mammalian cell lines (e.g., HEK-293, HepG2).	25
Chemical Tractability (C3)	Favorability for compound isolation and characterization.	LC-MS/MS complexity score*, presence of known nuisance compounds (e.g., polyphenols, tannins), chromatographic profile.	20
Pharmacological Profile (C4)	Broader ADME-Tox indicators.	Solubility, stability in assay buffer, PAINS alerts (computational), microsomal stability (if available).	15
Source & Sustainability (C5)	Supply and ethical considerations.	Biomass yield, cultivation time, conservation status (CITES), literature on known cultivation.	5

*LC-MS/MS complexity score = (Number of detectable peaks) / (Sum of peak intensities of top 5 constituents). A lower score suggests a less complex mixture dominated by fewer metabolites.

Diagram 1: Inventa MCDA workflow from extract to priority score.

Detailed Experimental Protocols for Inventa Criteria Assessment

Protocol 3.1: Primary Efficacy & Cytotoxicity Assays (C1 & C2 Data)

Objective: Determine IC50 against target pathogen and CC50 in host cells to calculate Selectivity Index (SI). Workflow:

• Extract Preparation: Reconstitute dried extract in DMSO to 10 mg/mL master stock. Perform serial dilution in assay medium (final DMSO ≤0.5%).
• Target Efficacy Assay (e.g., Antiplasmodial): Seed Plasmodium falciparum (3D7 strain) cultures at 1% parasitemia, 2% hematocrit in 96-well plates. Add extract dilutions. Incubate 72h (37°C, 5% O2, 5% CO2). Measure viability via SYBR Green I fluorescence (Ex/Em: 485/535 nm). Calculate % inhibition and IC50 using non-linear regression (e.g., GraphPad Prism).
• Host Cytotoxicity Assay: Seed HepG2 cells at 10,000 cells/well in 96-well plates. Adhere overnight. Add identical extract dilutions. Incubate 48h. Measure viability via resazurin reduction (Fluorescence: Ex/Em 560/590 nm). Calculate % cytotoxicity and CC50.
• Data Analysis: SI = CC50 (HepG2) / IC50 (Pf3D7).

Diagram 2: Workflow for efficacy and cytotoxicity assays.

Protocol 3.2: LC-MS/MS Profiling for Chemical Tractability (C3 Data)

Objective: Generate a chemical profile to calculate complexity score and screen for nuisance compounds. Method:

• Sample Prep: Dilute extract to 1 mg/mL in LC-MS grade MeOH. Centrifuge (15,000 x g, 10 min) to pellet insoluble material.
• LC Conditions (Vanquish UHPLC): Column: C18 (100 x 2.1 mm, 1.7 µm). Gradient: 5% B to 100% B over 18 min, hold 3 min. (A: H2O + 0.1% Formic Acid; B: ACN + 0.1% FA). Flow: 0.4 mL/min. Injection: 2 µL.
• MS Conditions (QE HF-X): ESI Positive/Negative switching. Full Scan: m/z 150-1500, Res: 120,000. Data-Dependent MS2: Top 5 ions, HCD fragmentation at 30 eV.
• Data Processing (MS-DIAL): Perform peak picking, alignment, and adduct deconvolution. Annotate features against public spectral libraries (e.g., GNPS).
• Calculate Complexity Score: (Total # of deconvoluted features) / (Sum of intensities of 5 most abundant features).

The Scientist's Toolkit: Research Reagent Solutions

Table 2: Essential Reagents & Materials for Inventa Workflow Implementation

Item	Function in Inventa Protocol	Example Product/Catalog #
In Vitro Parasite Culture	Primary efficacy model for anti-infective screening.	Plasmodium falciparum 3D7 strain (BEI Resources, MRA-102).
Mammalian Cell Line	Host cytotoxicity model for Selectivity Index.	HepG2 (ATCC, HB-8065).
Cell Viability Dye	Fluorescent readout for cytotoxicity and some efficacy assays.	Resazurin sodium salt (Sigma-Aldrich, R7017).
SYBR Green I Nucleic Acid Stain	High-sensitivity DNA stain for parasite viability.	Invitrogen SYBR Green I (Thermo Fisher, S7563).
UHPLC-MS Grade Solvents	Essential for reproducible chemical profiling (C3).	Acetonitrile (Fisher Chemical, A955-4), Water (Thermo, 51140).
C18 Reverse-Phase UHPLC Column	Core separation component for chemical profiling.	Waters ACQUITY UPLC BEH C18 (1.7 µm, 2.1 x 100 mm).
MCDA Analysis Software	Platform for data normalization, weighting, and IPS calculation.	Microsoft Excel with Solver Add-in, or R with MCDA package.

Data Normalization & IPS Calculation

Raw data from disparate assays are normalized to a 0-1 scale (1 = best performance) using benefit/cost functions.

For Benefit Criteria (e.g., Efficacy - lower IC50 is better): Normalized Score = (Max_IC50 - Sample_IC50) / (Max_IC50 - Min_IC50) For Cost Criteria (e.g., Complexity Score - lower is better): Normalized Score = (Max_Score - Sample_Score) / (Max_Score - Min_Score)

The IPS is computed as: IPS = Σ (Criterion_Weight_i * Normalized_Score_i)

Table 3: Hypothetical Inventa Scoring for Three Candidate Extracts

Extract ID	C1: IC50 (µg/mL) [Norm]	C2: SI [Norm]	C3: Complexity [Norm]	C4: Solubility (µg/mL) [Norm]	C5: Supply Score [Norm]	IPS (Rank)
EXT-022	1.2 [0.95]	>50 [1.00]	0.8 [0.90]	150 [0.80]	7/10 [0.70]	0.91 (1)
EXT-156	0.8 [1.00]	5 [0.25]	3.5 [0.10]	25 [0.10]	9/10 [0.90]	0.58 (2)
EXT-089	15.0 [0.00]	>100 [1.00]	1.2 [0.85]	>200 [1.00]	4/10 [0.40]	0.50 (3)

Weights: C1:0.35, C2:0.25, C3:0.20, C4:0.15, C5:0.05. EXT-022 excels in safety & tractability, earning top IPS despite not having the best IC50.

The Inventa MCDA framework provides a transparent, modular, and quantitative system for prioritizing natural extracts. By integrating multi-faceted data into a single IPS, it reduces bias in lead selection, maximizes the potential of identifying developable scaffolds, and provides a structured decision-support tool documented within the broader thesis on rational natural product discovery.

The journey from identifying a bioactive "hit" in a natural extract to prioritizing a refined "lead" compound is a critical, multi-parameter challenge in drug discovery. This process is framed within the broader thesis of the Inventa scoring system, a proprietary, data-driven framework designed to objectively evaluate and rank natural extracts and their constituent compounds. Inventa integrates biological activity, chemical tractability, and early ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) predictions into a single, comparable score, enabling systematic progression from screening to lead development.

Key Experimental Protocols & Workflows

Protocol 2.1: Primary High-Throughput Screening (HTS) for Hit Identification

Objective: Identify initial bioactive hits from a library of natural extracts in a target-based or phenotypic assay. Detailed Methodology:

• Plate Preparation: Dispense 20 µL of assay buffer (e.g., PBS with 1% DMSO) into each well of a 384-well microplate.
• Compound/Extract Addition: Using a liquid handler, transfer 100 nL of pre-diluted natural extract (typically at 1 mg/mL in DMSO) from a source plate to the assay plate. Include controls: 32 wells for positive control (100% effect) and 32 wells for negative control (0% effect).
• Target Incubation: Add 20 µL of the target (e.g., enzyme at 2x final concentration) to all wells. Seal and incubate for 30 minutes at 25°C.
• Substrate Addition: Add 20 µL of substrate/developer solution (at 2x final concentration) to initiate the reaction.
• Signal Detection: Incubate for the prescribed time (e.g., 60 min) and read the signal (fluorescence, luminescence, absorbance) using a plate reader.
• Data Analysis: Calculate % inhibition/activation for each well: %(Activity) = 100 * (Sample – Negative Ctrl) / (Positive Ctrl – Negative Ctrl). Extracts showing >50% activity at the test concentration are flagged as primary hits.

Protocol 2.2: Hit Confirmation & Counter-Screen Assay

Objective: Confirm the activity of primary hits and assess specificity against related targets or general interference (e.g., assay artifacts). Methodology:

• Dose-Response: Re-test confirmed hits in a 10-point, 1:3 serial dilution series (from 100 µg/mL to 0.05 µg/mL) in triplicate using the primary assay protocol.
• Counter-Screen: Run the same dilution series in a related but undesirable target assay (e.g., a kinase counter-screen for a kinase hit) or an interference assay (e.g., fluorescence quenching test for a fluorescent readout).
• Analysis: Calculate IC50/EC50 values using a four-parameter logistic (4PL) curve fit. Prioritize hits with potent activity in the primary assay (IC50 < 10 µg/mL) and >10-fold selectivity versus the counter-screen.

Protocol 2.3: Liquid Chromatography-Mass Spectrometry (LC-MS) Dereplication

Objective: Rapidly identify known compounds within active extracts to prioritize novel chemistry. Methodology:

• Sample Preparation: Reconstitute 1 mg of active natural extract in 1 mL of LC-MS grade methanol. Centrifuge at 14,000g for 10 minutes.
• LC Conditions: Inject 5 µL onto a C18 column (2.1 x 100 mm, 1.7 µm). Use a gradient from 5% to 95% acetonitrile (with 0.1% formic acid) over 18 minutes at 0.4 mL/min.
• MS Conditions: Use a high-resolution Q-TOF mass spectrometer in positive electrospray ionization (ESI+) mode. Scan range: 100-2000 m/z.
• Data Processing: Compare acquired MS/MS spectra and retention times against in-house and public databases (e.g., GNPS, DNP). Annotate known bioactive compounds (e.g., mycotoxins, frequent hitters).

Protocol 2.4: Early ADMET Profiling (Tier 1)

Objective: Obtain preliminary ADMET data for lead prioritization. Methodology:

• Metabolic Stability (Microsomal): Incubate 1 µM compound with 0.5 mg/mL human liver microsomes in PBS. Quench with acetonitrile at 0, 5, 10, 20, and 30 minutes. Analyze by LC-MS to determine half-life (T1/2).
• Permeability (PAMPA): Add 200 µL of 100 µM compound in PBS to donor plate. Filter plate (acceptor) contains PBS. Seal and incubate 4 hours. Measure concentration in both compartments by UV to calculate effective permeability (Pe).
• Cytotoxicity (HEK293): Seed cells at 10,000 cells/well. Treat with compound for 48 hours in a 10-point dose-response. Measure viability via CellTiter-Glo luminescent assay. Calculate CC50.

Data Presentation: Inventa Scoring Metrics

Table 1: Inventa Scoring Parameters for Lead Prioritization

Parameter	Assay/Measurement	Weight (%)	Score Range	Ideal Value
Potency	IC50 in primary target assay	25	1-10	IC50 < 1 µM (Score: 10)
Selectivity	Ratio (IC50 Counter-screen / IC50 Primary)	20	1-10	Selectivity > 50-fold (Score: 10)
Chemical Novelty	Database match (Dereplication)	15	1-10	No known compound match (Score: 10)
Purity & Tractability	LC-MS purity, compound class "drug-likeness"	15	1-10	Purity >90%, favorable scaffold (Score: 10)
ADMET Profile	Microsomal T1/2, PAMPA Pe, Cytotoxicity CC50	25	1-10	T1/2 >30 min, Pe > 2x10⁻⁶ cm/s, CC50 > 30 µM (Score: 10)
Total Inventa Score	Weighted Sum	100	1-10	≥7.5 for Lead Progression

Table 2: Example Prioritization of Three Hypothetical Natural Extracts

Extract ID	Potency (IC50, µg/mL)	Selectivity (Fold)	Novelty (Known Hit?)	Purity/Tractability	ADMET (Tier 1)	Inventa Score	Rank
NP-A001	0.5 (Score: 9)	25x (Score: 7)	Novel (Score: 10)	85%, Good (Score: 8)	Good (Score: 8)	8.3	1
NP-B234	5.0 (Score: 6)	100x (Score: 10)	Known Kinase Inhibitor (Score: 2)	95%, Excellent (Score: 10)	Moderate (Score: 6)	6.4	3
NP-C567	2.0 (Score: 7)	15x (Score: 5)	Novel (Score: 10)	70%, Moderate (Score: 6)	Excellent (Score: 9)	7.3	2

Visualizations

Title: Hit to Lead Prioritization Workflow

Title: Inventa Scoring Algorithm Components

The Scientist's Toolkit: Key Research Reagent Solutions

Table 3: Essential Reagents & Kits for Hit-to-Lead Experiments

Item/Kit Name	Vendor Examples	Primary Function in Workflow
Target-Specific HTS Assay Kit (e.g., Kinase-Glo, ADP-Glo)	Promega, Thermo Fisher	Enables homogeneous, high-throughput primary screening for specific enzyme classes.
Human Liver Microsomes (Pooled)	Corning, Xenotech	Critical for in vitro assessment of Phase I metabolic stability (T1/2).
PAMPA Plate System	pION, Corning	Measures passive permeability for early absorption prediction.
Cell Viability Assay (CellTiter-Glo)	Promega	Luminescent assay for cytotoxicity profiling on mammalian cell lines.
LC-MS Grade Solvents & Columns (e.g., Acquity UPLC BEH C18)	Waters, Agilent	Essential for high-resolution chromatographic separation prior to mass spec analysis.
Compound Management System (e.g., Echo Liquid Handler)	Labcyte, Beckman	Enables precise, non-contact transfer of extracts/compounds for dose-response and reformatting.
Natural Product Databases (DNP, MarinLit, GNPS)	CRC Press, GMELIN	Digital dereplication tools to identify known compounds and prioritize novelty.

Application Notes: Stakeholder Integration in Inventa-Prioritized Natural Product Research

The Inventa scoring algorithm provides a quantitative framework for prioritizing natural extracts based on multi-parametric analysis, including bioactivity, chemical diversity, ADMET properties, and source sustainability. Its utility is maximized when its outputs are strategically leveraged by distinct, collaborating stakeholders.

The Inventa Scoring Framework

Inventa generates a composite score (0-100) derived from weighted subscores. The following table summarizes the core quantitative metrics used for prioritization.

Table 1: Inventa Scoring Metrics and Weighted Subscores

Metric Category	Subscore Components	Typical Weight (%)	Data Source	Ideal Range for High Score
Bioactivity	Primary Target IC50/EC50; Selectivity Index; Cytotoxicity (CC50)	35	HTS, phenotypic assays	Low IC50/EC50, High SI (>10), High CC50
Chemical Profile	LC-MS/MS Compound Diversity; Novelty Score (% unknown features); Dereplication Hit Count	25	LC-MS/MS, NMR, Databases	High Diversity, Moderate Novelty (20-40%), Low Dereplication Hits
ADMET Predictions	Predicted LogP; CYP450 Inhibition Risk; hERG Alert; Bioavailability Score	25	In silico Tools (e.g., SwissADME)	LogP <5, Low CYP/hERG risk, Bioavailability >30%
Process & Supply	Extract Yield (% w/w); Source Abundance/Renewability Score; Stability Preliminary Data	15	Extraction Logs, Ecological Data, Forced Degradation	Yield >0.5%, High Renewability, Stable >1 month

Stakeholder-Specific Protocols & Benefits

Protocol 2.1: For Researchers (Biology & Discovery)

Title: Validation of Inventa-Top-Scoring Extracts in Secondary In Vitro and Mechanism-of-Action Assays. Objective: Confirm the bioactivity predicted by Inventa's primary screen and initiate mechanistic studies. Materials & Workflow: See Diagram A and The Scientist's Toolkit Table.

Procedure:

• Reconstitution: Take the top 3-5 Inventa-prioritized, lyophilized extracts. Reconstitute in DMSO to a stock concentration of 50 mg/mL. Sonicate for 15 minutes and centrifuge at 15,000 x g for 10 minutes to remove particulates.
• Dose-Response Confirmation: Perform an 8-point, 1:3 serial dilution of each extract in the relevant cell-based or enzymatic assay (derived from primary HTS). Run in triplicate. Calculate IC50/EC50 values. Success Criterion: IC50 within one log of the primary HTS result.
• Selectivity Assessment: Repeat the dose-response in two related but off-target assays or in non-disease relevant cell lines. Calculate a Selectivity Index (SI = CC50 or Off-target IC50 / Primary IC50). An SI >10 strongly supports target engagement.
• Pathway Analysis: For extracts meeting confirmation criteria, use a pathway reporter array (e.g., luciferase-based) or phospho-kinase array. Treat cells at the IC80 concentration for 4, 8, and 24 hours. Identify significantly modulated pathways. See Diagram B for generalized workflow.
• Fractionation Guidance: Use Inventa's LC-MS chemical diversity data to select the lead extract for bioassay-guided fractionation. Prioritize extracts with a high density of UV peaks in the active chromatographic region.

Protocol 2.2: For Pharmacologists (ADMET & PK/PD)

Title: Early In Vitro ADMET Profiling for Inventa-Prioritized Lead Extracts and Active Fractions. Objective: Translate Inventa's in silico ADMET predictions into experimental data to de-risk downstream development. Procedure:

• Metabolic Stability: Incubate the extract (10 µM equivalent of key marker compound) with pooled human liver microsomes (0.5 mg/mL) in NADPH-regenerating system. Sample at 0, 5, 15, 30, 60 minutes. Quench with acetonitrile. Analyze remaining parent markers by LC-MS/MS. Calculate in vitro t1/2 and Clint.
• Permeability Assessment: Perform a Caco-2 cell monolayer assay. Apply extract (100 µg/mL) to the apical chamber. Sample from basolateral chamber at 0, 30, 60, 120 minutes. Measure apparent permeability (Papp). Papp >10 x 10⁻⁶ cm/s suggests good absorption potential.
• CYP450 Inhibition: Incubate probe substrates for CYP3A4, 2D6, and 2C9 with human liver microsomes in the presence of three concentrations of the extract. Measure metabolite formation by LC-MS/MS relative to vehicle control. Flag extracts causing >50% inhibition at 10 µg/mL.
• Plasma Protein Binding: Use rapid equilibrium dialysis (RED). Spike extract into plasma compartment (100 µg/mL). Dialyze against PBS (pH 7.4) for 4 hours at 37°C. Quantify free concentration in buffer. Calculate % bound.

Table 2: Decision Matrix from Early ADMET Data

Parameter	Assay	Go/No-Go Threshold (Per Extract)	Pharmacologist Action
Metabolic Stability	Microsomal Clint	Clint > 50 µL/min/mg = High Clearance	Flag for structural modification of components.
Permeability	Caco-2 Papp	Papp < 2 (Low), 2-10 (Moderate), >10 (High) x 10⁻⁶ cm/s	Recommend formulation strategy for low Papp.
CYP Inhibition	% Inhibition at 10 µg/mL	>50% inhibition of major CYP (3A4/2D6)	Flag for high drug-drug interaction risk.
Plasma Binding	% Bound	>95% bound may limit tissue distribution	Note for PK/PD modeling.

Protocol 2.3: For Process Chemists (Scale-Up & Isolation)

Title: Systematic Scale-Up Extraction and Compound Isolation Based on Inventa Process Metrics. Objective: Efficiently translate small-scale active extracts into gram quantities of characterized material for preclinical studies. Procedure:

• Scale-Up Feasibility Review: Consult Inventa's Process & Supply subscore. Prioritize extracts with high yield (>0.5%) and excellent source sustainability data.
• Optimized Bulk Extraction: Scale the original extraction method (e.g., 70% EtOH, room temperature) by a factor of 1000, maintaining solvent-to-feed ratio. Use a rotary evaporator for concentration, followed by lyophilization to obtain a dry, stable intermediate.
• HPLC Method Translation: Scale the analytical HPLC-UV method used for chemical profiling to preparative HPLC. Adjust column dimensions, particle size, and flow rate while maintaining linear velocity. Perform iterative injections to collect the major UV-active peaks.
• Stability-Indicating Method Development: Subject the bulk extract to stress conditions (heat, light, acid/base) based on Inventa's preliminary stability flag. Develop an HPLC method that separates degradation products from major constituents for quality control.
• Dereplication Integration: Submit isolated fractions for rapid LC-MS/MS and 1D NMR analysis. Cross-reference data with Inventa's dereplication list to avoid re-isolation of known compounds and focus resources on novel chemical space.

The Scientist's Toolkit: Key Research Reagent Solutions

Table 3: Essential Materials for Featured Protocols

Item	Function	Example Vendor/Product Code
Human Liver Microsomes (Pooled)	In vitro model for Phase I metabolic stability and CYP inhibition studies.	Corning, product #452117
Caco-2 Cell Line	Model for predicting intestinal permeability and absorption.	ATCC, product #HTB-37
Rapid Equilibrium Dialysis (RED) Device	High-throughput measurement of plasma protein binding.	Thermo Fisher, product #89810
LC-MS/MS System (Triple Quadrupole)	Quantification of marker compounds, metabolites, and ADMET assay analytes.	Sciex QTRAP series
Preparative HPLC System	Isolation of milligram to gram quantities of compounds from scaled-up extracts.	Agilent 1260 Prep HPLC
Pathway Reporter Array (Luciferase)	High-throughput profiling of signaling pathway activation/inhibition.	Qiagen Cignal Reporter Assay
Lyophilizer (Freeze Dryer)	Stabilization of extracts and isolated compounds for long-term storage.	Labconco FreeZone

Mandatory Visualizations

Diagram A: Integrated Workflow from Inventa Score to Lead

Diagram B: Signaling Pathway Analysis Workflow

Deconstructing Inventa: A Step-by-Step Guide to Scoring Natural Extracts

Application Notes

Within the Inventa framework for natural extract prioritization, Pillar 1 provides the foundational quantitative assessment of biological activity. It translates raw assay data into a standardized, comparable scoring system. This tripartite scoring—IC50 (potency), Efficacy (maximal effect), and Selectivity (target specificity)—enables researchers to rank diverse natural extracts against a defined molecular target, filtering out non-specific cytotoxic effects and identifying true hits for downstream investigation in Pillars 2-4. The protocols below are designed for high-throughput screening (HTS) environments typical in early drug discovery.

Table 1: Bioactivity Scoring Tiers for Inventa Prioritization

Score Tier	IC50 Range (µM)	Efficacy (% of Control)	Selectivity Index (SI)*	Interpretation & Action
High Priority	< 1	> 80%	> 50	High potency, full efficacy, and excellent selectivity. Prioritize for full mechanism-of-action (MOA) studies.
Medium Priority	1 - 10	50% - 80%	10 - 50	Moderate activity. Requires counter-screening and dose-response confirmation.
Low Priority	10 - 30	30% - 50%	5 - 10	Weak activity. May be deprioritized unless novelty is high.
Negative / Cytotoxic	> 30 (or n.d.)	< 30%	< 5	Inactive or non-selectively cytotoxic. Exclude from further study.

n.d. = not determinable; *SI = IC50 on primary target / IC50 on nearest ortholog or related target.

Table 2: Example Scoring Output for Hypothetical Natural Extracts (Target: Kinase XYZ)

Extract ID	IC50 (µM)	Efficacy (%)	Cytotoxicity IC50 (µM)	Selectivity Index (SI)	Pillar 1 Score
NE-α-001	0.45 ± 0.12	95 ± 5	>100	>222	9.8
NE-β-055	5.70 ± 1.3	72 ± 8	45 ± 10	7.9	6.2
NE-δ-123	25.0 ± 5.0	40 ± 12	28 ± 7	1.1	2.0

Composite score calculated as: Score = (10 - Log10(IC50)) * (Efficacy/100) * Log10(SI). Scores normalized to 10-point scale.

Experimental Protocols

Protocol 1: Dose-Response IC50 & Efficacy Determination (Fluorescence-Based Kinase Assay)

Objective: To determine the half-maximal inhibitory concentration (IC50) and maximal percentage inhibition (Efficacy) of a natural extract against a purified kinase target.

Workflow:

• Plate Preparation: Dilute test extracts in DMSO to create a 10-point, 1:3 serial dilution (e.g., from 100 µM to 0.05 µM final top concentration). Use a 384-well assay plate.
• Reaction Mixture: Add kinase buffer, ATP (at Km concentration), fluorogenic peptide substrate, and the purified kinase to each well. Final DMSO concentration must be ≤1%.
• Inhibition Reaction: Pre-incubate test compound/extract with kinase for 15 minutes before initiating reaction with ATP/MgCl2.
• Detection: Use a coupled detection system (e.g., ADP-Glo or fluorescence polarization). Read plate on a multi-mode microplate reader.
• Controls: Include positive control (known inhibitor, e.g., Staurosporine), negative control (DMSO only), and background control (no kinase).
• Data Analysis: Normalize data to positive (0% activity) and negative (100% activity) controls. Fit normalized dose-response data to a four-parameter logistic (4PL) model: Y = Bottom + (Top-Bottom)/(1+10^((LogIC50-X)*HillSlope)). Extract IC50 and Efficacy (Bottom asymptote).

Protocol 2: Selectivity Index (SI) Determination via Counter-Screen Panel

Objective: To assess the specificity of an active extract by testing against a panel of related kinases or anti-targets, and a general cytotoxicity assay.

Part A: Kinase Panel Screening:

• Panel Design: Select a panel of 10-20 kinases from the same family (e.g., kinome) or closest phylogenetic orthologs to the primary target.
• Single-Concentration Screen: Test the extract at a single concentration (e.g., 10 µM or 10x IC50) against the entire panel using a standardized kinase activity assay (e.g., mobility shift).
• Hit Confirmation: For kinases showing >50% inhibition in the single-point screen, perform a full dose-response (Protocol 1) to determine IC50.
• SI Calculation: SI = IC50 (Most Potent Anti-Target) / IC50 (Primary Target). A higher SI indicates greater selectivity.

Part B: Cytotoxicity Counter-Screen (Cell-Based):

• Cell Culture: Seed adherent cells (e.g., HEK293 or HepG2) in a 96-well plate.
• Treatment: Treat cells with the same dilution series used in the primary biochemical assay for 48-72 hours.
• Viability Assessment: Use a resazurin (Alamar Blue) assay. Add reagent, incubate 2-4 hours, and measure fluorescence (Ex 560nm/Em 590nm).
• Data Analysis: Calculate CC50 (cytotoxic concentration 50%) using a 4PL curve fit. A CC50 >> biochemical IC50 suggests selective target engagement.

The Scientist's Toolkit

Table 3: Key Research Reagent Solutions for Pillar 1 Assays

Item	Function in Protocol	Example Product/Catalog
Purified Recombinant Kinase	Primary target enzyme for biochemical activity assays.	Recombinant Human [Kinase XYZ], active, >90% purity.
ADP-Glo Kinase Assay Kit	Universal, luminescent detection of kinase activity by measuring ADP production.	Promega, V9101. Enables homogenous, HTS-compatible screening.
Fluorogenic Peptide Substrate	Kinase-specific substrate whose phosphorylation increases fluorescence.	5-FAM-labeled peptide (e.g., for Ser/Thr kinases).
Staurosporine	Broad-spectrum kinase inhibitor; standard positive control for inhibition assays.	Sigma-Aldrich, S5921.
Resazurin Sodium Salt	Cell-permeable dye used in cytotoxicity assays; reduction by viable cells yields fluorescent resorufin.	Sigma-Aldrich, R7017.
384-Well, Low-Volume, Black Assay Plates	Optimal microplate format for HTS dose-response curves, minimizing reagent use.	Corning, 3820.
Automated Liquid Handler	For accurate, reproducible serial dilutions and compound/reagent transfer in HTS.	Beckman Coulter Biomek i7.
Multimode Microplate Reader	To read fluorescence, luminescence, or absorbance endpoints from assay plates.	BioTek Synergy H1.

Diagrams

Title: Bioactivity Scoring Workflow

Title: Kinase Inhibition Signaling Logic

Application Notes: Integrating LC-MS/MS and NMR for Inventa Scoring

Within the Inventa scoring framework for natural extract prioritization, Pillar 2 quantifies the chemical complexity and novelty of an extract. This dual-analytical approach generates a comprehensive chemical profile that feeds critical metrics into the overall Inventa score, guiding rational selection for downstream bioactivity screening.

1. Quantitative Chemical Profiling via LC-MS/MS: This high-sensitivity technique provides a semi-quantitative overview of secondary metabolites. Key data outputs for Inventa scoring include:

• Peak Count & Diversity: A proxy for chemical richness.
• MS/MS Spectral Library Hits: Identifies known compounds, allowing for the calculation of a "novelty ratio."
• Intensity-Based Distribution: Informs on major and minor constituents.

2. Structural Elucidation & Quantification via NMR Fingerprinting: ¹H NMR spectroscopy offers a universal, quantitative snapshot of the extract's metabolome. Key contributions to Inventa scoring are:

• Absolute Quantification: Enables precise concentration determination of major constituents without standards.
• Structural Fingerprint: Confirms compound classes and identifies unique structural motifs.
• Mixture Complexity Index: Derived from spectral dispersion and signal overlap.

Table 1: Inventa Scoring Metrics from Pillar 2 Data

Metric	Analytical Source	Calculation	Score Contribution
Richness Index (RI)	LC-MS/MS	Total number of distinct peaks (S/N > 10) per mg of extract.	0-25 points
Novelty Ratio (NR)	LC-MS/MS	1 - (∑ Library Matched Peaks / Total Peaks).	0-30 points
Major Constituent Clarity (MCC)	¹H NMR	Sum of integrals of clearly resolved singlet peaks (δ 0.5-10 ppm).	0-20 points
Dereplication Confidence (DC)	LC-MS/MS & NMR	Concordance between LC-MS library match and NMR predicted structure (Binary: Yes/No).	0-25 points

Experimental Protocols

Protocol A: Untargeted LC-MS/MS Profiling for Inventa Objective: Generate a reproducible metabolic fingerprint for richness and novelty scoring.

• Sample Prep: Reconstitute 1.0 mg of dried extract in 1 mL LC-MS grade methanol. Sonicate for 15 min, centrifuge at 14,000 × g for 10 min. Filter through 0.22 µm PTFE membrane.
• LC Conditions:
  • Column: C18 (2.1 x 100 mm, 1.7 µm).
  • Gradient: Water (A) and Acetonitrile (B), both with 0.1% Formic acid. 5% B to 95% B over 18 min, hold 2 min.
  • Flow Rate: 0.3 mL/min. Injection Volume: 2 µL.
• MS Conditions:
  • Instrument: Q1) Q-TOF or Orbitrap mass analyzer.
  • Ionization: ESI positive/negative mode switching.
  • Scan Range: m/z 100-1500.
  • Data-Dependent Acquisition (DDA): Top 10 most intense ions per cycle selected for MS/MS fragmentation.
• Data Processing: Use software (e.g., MZmine, MS-DIAL) for peak picking, alignment, and adduct deconvolution. Query public libraries (GNPS, MassBank).

Protocol B: ¹H NMR Fingerprinting for Quantitative Profiling Objective: Obtain a quantitative and structurally informative profile for mixture analysis.

• Sample Preparation: Precisely weigh 5.0 mg of extract into 1.5 mL tube. Add 600 µL of deuterated methanol (CD₃OD) or DMSO-d6. Vortex for 1 min, sonicate 15 min, centrifuge. Transfer 550 µL to a 5 mm NMR tube.
• NMR Acquisition:
  • Instrument: 600 MHz spectrometer with cryoprobe.
  • Pulse Sequence: Standard 1D NOESY-presat (noesygppr1d) for water suppression.
  • Parameters: Spectral width 20 ppm, offset 4.7 ppm. Temperature 298 K. Acquisition Time: ~15 min (128 scans).
• Data Processing & Analysis:
  • Process with TopSpin or MestReNova: Apply zero-filling to 128k, exponential line broadening (0.3 Hz), Fourier transform, phase and baseline correction.
  • Reference TMS or residual solvent peak.
  • Use Chenomx NMR Suite or similar for spectral profiling and compound quantification via electronic reference.

The Scientist's Toolkit: Research Reagent Solutions

Item	Function in Pillar 2 Analysis
Hybrid Quadrupole-Orbitrap Mass Spectrometer	High-resolution, accurate-mass (HRAM) detection for precise molecular formula assignment and MS/MS structural elucidation.
Cryogenically Cooled NMR Probe (Cryoprobe)	Dramatically increases sensitivity for ¹H NMR, enabling analysis of limited natural product samples.
Deuterated NMR Solvents (e.g., CD₃OD, DMSO-d6)	Provides a field-frequency lock for stable NMR acquisition and minimizes interfering solvent signals.
Solid Phase Extraction (SPE) Cartridges (C18, Diol)	For rapid fractionation or clean-up of crude extracts to reduce complexity prior to LC-MS analysis.
Metabolomics Software (e.g., MZmine, MS-DIAL, GNPS)	Enables automated processing of LC-MS/MS data, feature detection, alignment, and database matching for dereplication.
Quantitative NMR Software (e.g., Chenomx NMR Suite)	Libraries and tools for identifying and quantifying metabolites directly from 1D ¹H NMR spectra.

Pillar 2 Inventa Analysis Workflow

Inventa Score Calculation Logic

Introduction Within the Inventa scoring framework for natural extract prioritization, Pillar 3 is the critical translational gatekeeper. It applies in silico and in vitro predictive models to evaluate the pharmacokinetic and safety profiles of lead compounds identified from biological screening (Pillar 1) and mechanistic characterization (Pillar 2). This phase de-risks natural product leads by forecasting Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) and key druggability parameters early in the discovery pipeline, preventing costly late-stage attrition.

Application Notes

• Rationale for Early Integration: Traditional natural product research often defers ADMET assessment, leading to high failure rates due to poor bioavailability or toxicity. Pillar 3 embeds these predictions post-identification of active chemotypes, ensuring only extracts or fractions with favorable computational profiles advance to costly isolation.
• Hierarchical Filtration Strategy: The Inventa protocol employs a sequential filtration model.
  • Tier 1 (Computational): Uses the chemical structures of annotated features from LC-MS/MS to predict fundamental ADMET properties.
  • Tier 2 (High-Throughput In Vitro): For extracts passing Tier 1, key assays (e.g., metabolic stability, permeability) are performed on the crude or semi-purified material using pooled compound approaches.

• Key Predictive Endpoints: The following parameters are calculated or measured and integrated into a composite Pillar 3 score.

  Table 1: Core ADMET & Druggability Endpoints in Inventa Pillar 3

  Endpoint Category	Specific Parameter	Prediction Method/Tool	Ideal Range/Outcome for Lead
  Absorption	Human Intestinal Absorption (HIA)	QSAR Model (e.g., SwissADME)	>80% predicted absorption
  	Caco-2 Permeability (Papp)	In vitro assay (see Protocol A)	>20 x 10-6 cm/s
  Distribution	Plasma Protein Binding (PPB)	In vitro equilibrium dialysis	Moderate (80-95% bound)
  	Volume of Distribution (Vd)	QSAR Prediction	>0.15 L/kg (for systemic exposure)
  Metabolism	CYP450 Inhibition (3A4, 2D6)	In vitro fluorescence/LC-MS assay	IC50 > 10 µM
  	Microsomal/Hepatocyte Stability	In vitro T1/2 assay (see Protocol B)	T1/2 > 30 minutes
  Toxicity	hERG Channel Inhibition	In silico model (e.g., pkCSM)	Low predicted affinity (pIC50 < 5)
  	Ames Test (Mutagenicity)	In silico SAR model	Negative prediction
  Druggability	Lipinski's Rule of Five	Computational filter	≤1 violation
  	Quantitative Estimate of Drug-likeness (QED)	Computational score (e.g., RDKit)	QED > 0.5

Experimental Protocols

Protocol A: High-Throughput Caco-2 Permeability Assay for Natural Extract Fractions Purpose: To assess the intestinal permeability potential of semi-purified natural extract fractions in a cell-based model. Workflow:

• Cell Culture: Maintain Caco-2 cells in DMEM with 20% FBS. Seed on 96-well transwell inserts at high density. Culture for 21-25 days to ensure full differentiation and tight junction formation. Confirm monolayer integrity via TEER (>350 Ω·cm²).
• Sample Preparation: Re-dissolve test fractions (from Pillar 2 fractionation) in transport buffer (HBSS, 10 mM HEPES, pH 7.4). Include controls: High permeability (Propranolol) and low permeability (FITC-Dextran).
• Assay Execution: Add test sample to donor compartment (apical for A→B, basolateral for B→A). Collect samples from receiver compartment at 30, 60, 90, and 120 minutes.
• Analysis: Quantify compound abundance in donor and receiver samples using LC-MS/MS (aligning with Pillar 1 annotation). Calculate apparent permeability (P_app).
• Data Interpretation: P_app (A→B) > 20 x 10^-6 cm/s indicates high permeability. Evaluate efflux ratio (P_app (B→A) / P_app (A→B)) to flag potential P-gp substrates (ratio > 2.5).

Protocol B: Microsomal Metabolic Stability Assay Purpose: To determine the in vitro half-life (T_1/2) and intrinsic clearance (CL_int) of lead compounds within a natural extract pool. Workflow:

• Incubation Preparation: Prepare 0.5 mg/mL mouse or human liver microsomes in 100 mM phosphate buffer (pH 7.4). Pre-warm at 37°C. Pre-incubate test extract/fraction (final concentration ~1 µg/mL of lead compound equivalent) with microsomes for 5 minutes.
• Reaction Initiation: Start reaction by adding NADPH regenerating system (final 1 mM NADP+, 10 mM Glucose-6-P, 1 U/mL G6PDH). Use negative controls without NADPH.
• Time-Course Sampling: Aliquot reaction mixture at T = 0, 5, 10, 20, 30, and 60 minutes into a cold quenching solution (acetonitrile with internal standard).
• Sample Processing: Centrifuge to precipitate proteins. Analyze supernatant by LC-MS/MS, monitoring the parent ion intensity of the lead annotated compound(s).
• Kinetic Analysis: Plot Ln(peak area) vs. time. Calculate slope (k). Determine T_1/2 = 0.693/k. Calculate CL_int = (0.693 / T_1/2) * (Incubation Volume / Microsome Protein).

Visualizations

Title: Inventa Pillar 3 Hierarchical Filtration Workflow

Title: Key Computational Predictions for Druggability Score

The Scientist's Toolkit

Table 2: Essential Research Reagent Solutions for Pillar 3 Protocols

Reagent / Material	Supplier Examples	Function in Protocol
Differentiated Caco-2 Cell Monolayers	ATCC, Sigma-Aldrich	Gold-standard in vitro model for predicting human intestinal permeability.
96-well Transwell Plate Systems	Corning, Greiner Bio-One	Permeable supports for culturing cell monolayers for permeability assays.
Pooled Human Liver Microsomes (HLM)	Corning, Xenotech	Enzyme source for in vitro metabolic stability and CYP inhibition studies.
NADPH Regenerating System	Promega, Sigma-Aldrich	Provides constant NADPH supply to sustain cytochrome P450 enzyme activity.
LC-MS/MS System (QQQ or Q-TOF)	Agilent, Sciex, Waters	Quantifies compound depletion (stability) or transport (permeability) with high sensitivity.
Precision Analytical Standards (Propranolol, Verapamil, etc.)	Sigma-Aldrich, Tocris	Serve as control compounds for assay validation and data normalization.
In Silico ADMET Prediction Platform (e.g., SwissADME, pkCSM)	Public Web Tools	Provides initial computational profiling of annotated compound structures.

1. Application Notes on Supply Chain & Scalability for Extract Prioritization

Within the Inventa scoring framework for natural extract prioritization, Pillar 4 provides a critical counterbalance to bioactivity scores (Pillar 1-3). It evaluates the practical feasibility and ethical responsibility of developing a candidate extract into a sustainable commercial supply. This assessment mitigates the significant downstream risk of clinical failure due to unreliable or unsustainable sourcing.

1.1 Key Assessment Verticals

• Sourcing Complexity: Evaluates the geographic, regulatory, and taxonomic challenges associated with raw material procurement.
• Scalability & Agronomy: Assesses the potential for cultivation, yield optimization, and biomass availability without ecological harm.
• Sustainability & Stewardship: Measures environmental impact, conservation status, and compliance with frameworks like the Nagoya Protocol.
• Supply Chain Resilience: Analyzes geopolitical stability, processing infrastructure, and vulnerability to disruptions.

1.2 Quantitative Scoring Metrics for Inventa Scores (1-10, where 10 is optimal) are assigned for each vertical. The following table summarizes core metrics and data sources.

Table 1: Pillar 4 Quantitative Scoring Metrics

Vertical	Metric	Data Source/Protocol	Optimal Score (10) Indicates
Sourcing Complexity	Geographic Accessibility Index	Geopolitical risk databases, CITES listings	Cultivated in multiple stable regions
	Taxonomic Identification Certainty	DNA barcoding (see Protocol 4.1)	Species resolved with >99.9% confidence
	Wild Collection vs. Cultivation %	Supplier audits, literature	100% cultivated from controlled sources
Scalability	Estimated Annual Biomass (kg/ha/yr)	Field trial data, agronomy studies	High, reliable yield with annual harvest
	Active Compound Yield (%)	HPLC quantification (see Protocol 4.2)	High, consistent concentration
	Agricultural Readiness Level (ARL)	Adapted from NASA TRL scales	ARL 9 (commercial production proven)
Sustainability	IUCN Red List Status	IUCN Red List website	‘Least Concern’ for cultivated source
	Soil/Water Impact Score	Life Cycle Assessment (LCA) studies	Negligible impact, regenerative practices
	Nagoya Protocol Compliance	ABS Clearing-House, Material Transfer Agreements	Full documented compliance
Supply Chain Resilience	Supplier Concentration Index	# of qualified suppliers	Multiple independent, qualified suppliers
	Processing Step Complexity	Supply chain mapping	Minimal, standardized processing steps
	Lead Time Variability (days)	Historical procurement data	Low variance, predictable timeline

2. Experimental Protocols

Protocol 4.1: DNA Barcoding for Species Authentication & CITES Compliance Purpose: To unambiguously identify the taxonomic source of a natural extract, ensuring compliance with conservation regulations and preventing adulteration. Workflow:

• Genomic DNA Extraction: Use a commercial kit (e.g., DNeasy Plant Mini Kit) from 20mg of dried biomass. Include negative control.
• PCR Amplification of Barcode Regions:
  • Primers: rbcL (forward: 5’-ATGTCACCACAAACAGAGACTAAAGC-3’; reverse: 5’-GTAAAATCAAGTCCACCRCG-3’) and ITS2 (forward: 5’-GCATCGATGAAGAACGCAGC-3’; reverse: 5’-TCCTCCGCTTATTGATATGC-3’).
  • Mix: 25μL reaction with standard Taq polymerase.
  • Cycling: 94°C for 5 min; 35 cycles of 94°C/30s, 52°C/40s, 72°C/1min; final extension 72°C/5min.
• Sequencing & Analysis: Purify PCR products, Sanger sequence. Assemble contigs. Query sequences against databases (GenBank, BOLD) using BLASTN. Confirm match with >99% identity to reference.
• CITES Check: Cross-reference identified species against current CITES Appendices.

Protocol 4.2: HPLC-DAD Quantification of Key Active Metabolites for Yield Assessment Purpose: To quantitatively determine the concentration of a target bioactive compound in raw biomass and standardized extract, critical for calculating scalability and economic viability. Workflow:

• Sample Preparation: Accurately weigh 50mg of finely powdered plant material. Extract with 5mL of 80% methanol (v/v) via sonication (30 min). Centrifuge, filter (0.22μm PVDF).
• Standard Curve: Prepare serial dilutions of an analytical standard of the target compound (e.g., berberine, curcumin).
• HPLC-DAD Analysis:
  • Column: C18, 150 x 4.6 mm, 5μm.
  • Mobile Phase: (A) 0.1% Formic acid in H2O, (B) Acetonitrile. Gradient: 5-95% B over 25 min.
  • Flow: 1.0 mL/min. Detection: DAD at λ-max of target compound.
  • Injection: 10μL of sample and standards in triplicate.
• Quantification: Integrate peak areas. Plot standard curve (area vs. concentration). Calculate compound concentration in sample (mg/g dry weight). Report mean ± SD.

3. Visualizations

Diagram 1: Pillar 4 Assessment & Protocol Integration Workflow

4. The Scientist's Toolkit: Key Research Reagent Solutions

Table 2: Essential Materials for Pillar 4 Experimental Assessment

Item	Function	Example Product/Catalog
Plant DNA Extraction Kit	Isolates high-quality genomic DNA for barcoding PCR.	Qiagen DNeasy Plant Mini Kit (69104)
Universal Barcode Primers	PCR primers for amplifying standard loci (rbcL, ITS2).	MilliporeSigma, custom oligos
C18 Reverse-Phase HPLC Column	Standard column for separating small molecule metabolites.	Agilent ZORBAX Eclipse Plus C18 (959990-902)
Analytical Standard of Target Compound	Critical for HPLC quantification and method validation.	e.g., ChromaDex (Berberine, Std-003)
Certified Reference Plant Material	Authenticated biomass for use as positive control in assays.	NIST SRM 3256 (Chaparral)
Life Cycle Assessment (LCA) Software	Models environmental impact of cultivation & processing.	SimaPro, OpenLCA
ABS Compliance Documentation Template	Ensures Nagoya Protocol compliance in material sourcing.	UN provided Model Agreement Clauses

Application Notes: Scoring for Natural Extract Prioritization in the Inventa Framework

Within the Inventa research thesis for natural product-based drug discovery, the selection of a scoring algorithm is critical for transforming multi-dimensional assay data into a single, actionable priority rank. This document contrasts the transparent, rule-based Weighted Sum Model (WSM) with the adaptive, pattern-recognizing Machine Learning (ML) integration, providing protocols for their application.

Quantitative Comparison of Scoring Approaches

Table 1: Core Algorithmic Characteristics & Performance Metrics

Feature	Weighted Sum Model (WSM)	Machine Learning Integration (e.g., Random Forest/Neural Net)
Core Principle	Linear combination of normalized feature scores multiplied by predefined weights.	Non-linear mapping of features to a score via a model trained on historical data.
Mathematical Form	Score = Σ (w_i * x_i), where w_i is weight, x_i is normalized value.	Score = f(x_1, x_2,..., x_n), where f is a learned, complex function.
Interpretability	High. Direct contribution of each parameter is transparent.	Low to Moderate. "Black box" nature; requires SHAP/LIME for interpretation.
Data Requirement	Low. Requires expert judgment for weight assignment.	High. Needs large, high-quality labeled datasets for training.
Adaptability	Static. Weights require manual re-evaluation for new data trends.	Dynamic. Model can retrain and adapt to new data patterns.
*Typical Validation R²	0.65 - 0.80 (on linear relationships)	0.75 - 0.95 (on complex, non-linear relationships)
Primary Risk	Expert bias in weight allocation; oversimplification.	Overfitting to training data; poor generalization to novel scaffolds.

*Validation R²: Coefficient of determination comparing predicted scores to expert validation panels on benchmark natural extract libraries.

Table 2: Inventa Workflow Application Suitability

Research Phase	Recommended Algorithm	Rationale
Initial Screening	Weighted Sum Model	Rules-based, transparent prioritization from limited initial data (e.g., yield, LC-MS novelty).
Secondary Validation	Hybrid: WSM for primary, ML for outliers	Combines WSM reliability with ML's ability to identify non-linear promising candidates.
Advanced Lead Opt.	Machine Learning Integration	Leverages large-scale multi-omic data (transcriptomics, metabolomics) for predictive bioactivity scoring.

Experimental Protocols

Protocol A: Implementing a Weighted Sum Model for Primary Extract Screening

Objective: To calculate a priority score for plant extracts based on pre-clinical parameters. Materials: See "Scientist's Toolkit" below. Procedure:

• Data Normalization: For each parameter (e.g., Yield, Purity, IC₅₀), min-max normalize raw data to a 0-1 scale.
• Weight Assignment: Convene a panel of 3-5 subject matter experts. Use the Analytic Hierarchy Process (AHP) to derive consensus weights for each parameter. Sum of all weights must equal 1.
• Score Calculation: Apply the formula: Priority Score = (w_yield * Norm_Yield) + (w_purity * Norm_Purity) + (w_potency * (1 - Norm_IC₅₀)) + (w_tox * (1 - Norm_Toxicity)).
• Ranking & Threshold: Rank extracts in descending order of Priority Score. Apply a pre-defined threshold (e.g., >0.65) for advancement.

Protocol B: Training a Random Forest Model for Bioactivity Prediction

Objective: To develop an ML model that predicts a composite bioactivity score from chemical fingerprint data. Procedure:

• Dataset Curation: Assemble a historical dataset of ≥500 natural extracts with known outcomes (e.g., active/inactive label, or continuous bioactivity score). Features include molecular descriptors (from LC-MS) and physicochemical properties.
• Feature Engineering: Perform feature scaling (StandardScaler) and selection (e.g., remove low-variance features, use SelectKBest).
• Model Training: Split data 80/20 into training and test sets. Using scikit-learn, train a RandomForestRegressor (or Classifier) with hyperparameter tuning via GridSearchCV (optimize nestimators, maxdepth).
• Validation & Integration: Validate model on the held-out test set. Require AUC-ROC >0.8 for classification or R² >0.7 for regression. Deploy the trained model as a scoring function within the Inventa pipeline.

Mandatory Visualizations

Title: Weighted Sum Model Scoring Workflow

Title: ML Model Training & Deployment Pipeline

The Scientist's Toolkit: Research Reagent Solutions

Item / Solution	Function in Scoring Algorithm Context
Analytic Hierarchy Process (AHP) Software (e.g., SuperDecisions)	Facilitates structured expert deliberation to derive consistent, unbiased weights for WSM parameters.
scikit-learn Python Library	Provides essential algorithms for ML integration (Random Forest, SVM, Neural Networks) and model validation tools.
SHAP (SHapley Additive exPlanations) Library	Enables interpretation of complex ML models by quantifying the contribution of each input feature to the final score.
Benchmark Natural Product Libraries (e.g., NCI Natural Products Set)	Gold-standard reference sets required for training and validating ML models against known bioactivities.
High-Content Screening (HCS) Assay Kits	Generates rich, multi-parameter bioactivity datasets (phenotypic responses) as high-dimensional inputs for ML scoring.
LC-MS with Molecular Networking (GNPS)	Provides chemical fingerprint data (molecular descriptors) as primary features for both WSM and ML scoring algorithms.

Within the broader thesis on the development and application of the Inventa scoring algorithm for natural extract prioritization, this document provides the essential Application Notes and Protocols. The core thesis posits that a multi-parametric scoring system, integrating bioactivity, chemical profiling, and cheminformatics-based drug-likeness predictions, can significantly enhance the efficiency of identifying promising natural product hits. This workflow details the practical steps to transform raw wet-lab data into a reliable, prioritized hit list using the Inventa framework.

The Inventa score is a composite index (0-1) designed to rank natural extracts. It is calculated from three weighted pillars:

• Pillar 1: Bioactivity Potency & Selectivity (Weight: 0.50). Derived from primary assay IC50/EC50 and counter-screen selectivity ratios.
• Pillar 2: Chemical Richness & Diversity (Weight: 0.30). Based on LC-MS/MS data: number of putative compounds, chemical class diversity, and presence of rare scaffolds.
• Pillar 3: Predicted Drug-Likeness & Toxicity (Weight: 0.20). Generated from in-silico predictions of physicochemical properties (e.g., LogP, molecular weight) and toxicity alerts.

Application Notes & Protocols

Protocol 1: Primary Bioactivity Screening & Data Input

Objective: To generate dose-response data for Inventa Pillar 1. Methodology:

• Cell-Based Viability Assay: Plate target cells (e.g., cancer cell line) in 384-well plates at 2,000 cells/well. Incubate for 24h.
• Compound Addition: Treat cells with a dilution series (typically 8 points, 1:3 serial dilution starting from 100 µg/mL) of each natural extract. Include DMSO vehicle and reference inhibitor controls.
• Incubation & Development: Incubate for 72h. Add CellTiter-Glo reagent, shake, and incubate for 10 minutes.
• Data Acquisition: Measure luminescence on a plate reader.
• Data Normalization & Analysis:
  • Normalize data: % Inhibition = 100 * (1 - (Lumsample - Lumblank)/(Lumvehicle - Lumblank)).
  • Fit normalized dose-response data to a 4-parameter logistic (4PL) model using software (e.g., GraphPad Prism).
  • Extract IC50 and Hill Slope values.

Table 1: Example Primary Screening Data for Inventa Input

Extract ID	Target IC50 (µg/mL)	Hill Slope	R² of Fit	% Inhibition at Max Conc.
NP-001	12.5	-1.2	0.99	98
NP-002	45.8	-0.8	0.97	85
NP-003	>100	N/A	N/A	<30

Protocol 2: LC-MS/MS Profiling for Chemical Richness

Objective: To generate data for Inventa Pillar 2. Methodology:

• Sample Preparation: Reconstitute 1 mg of active extract (IC50 < 100 µg/mL) in 1 mL of LC-MS grade methanol. Centrifuge, filter (0.22 µm PTFE).
• LC-MS/MS Analysis:
  • Column: C18 reversed-phase (2.1 x 100 mm, 1.7 µm).
  • Gradient: 5% to 95% Acetonitrile in water (0.1% Formic acid) over 18 min.
  • MS: Data-Dependent Acquisition (DDA) mode on a high-resolution Q-TOF. Collect full scan (70-1200 m/z) and top 10 MS/MS scans.
• Data Processing:
  • Use software (e.g., MZmine, MS-DIAL) for peak picking, alignment, and deconvolution.
  • Perform spectral library matching (e.g., GNPS, NIST) and in-silico fragmentation (SIRIUS) for compound annotation.
  • Output: List of putative compounds, chemical classes, and m/z values.

Table 2: Chemical Profiling Data Summary for Inventa Pillar 2

Extract ID	Total Putative Features	Unique Compound Classes	Putative Rare Scaffolds*
NP-001	150	8 (Alkaloids, Terpenes..)	2
NP-002	85	4 (Flavonoids, Acids)	0
*Rare scaffold defined as molecular framework not present in common databases.

Protocol 3: In-silico ADMET Prediction

Objective: To generate data for Inventa Pillar 3. Methodology:

• Input Preparation: From Protocol 2, select the top 10 most abundant putative compounds (by peak area) for each extract. Generate their SMILES strings.
• Prediction Pipeline: Submit SMILES strings to a batch prediction tool (e.g., SwissADME, ProTox-II).
• Key Parameters to Extract:
  • SwissADME: LogP (iLOGP), Molecular Weight, Number of H-bond donors/acceptors, Bioavailability Score.
  • ProTox-II: Predicted LD50 class, Hepatotoxicity, Carcinogenicity alerts.
• Data Aggregation: Calculate the average drug-likeness score and % of compounds without critical toxicity alerts per extract.

Inventa Score Calculation & Hit Prioritization

Formula: Inventa Score = (0.50 * P1) + (0.30 * P2) + (0.20 * P3) Where P1, P2, P3 are normalized scores (0-1) for each pillar.

Calculation Steps:

• Normalize each pillar: For each extract, convert raw data to a 0-1 scale relative to the batch's best performer.
• Apply weights: Multiply normalized scores by pillar weights.
• Sum & Rank: Sum weighted scores to get final Inventa Score. Rank extracts descending.

Table 3: Inventa Score Calculation & Final Prioritized Hit List

Extract ID	P1 (Bioactivity)	P2 (Chemistry)	P3 (ADMET)	Inventa Score	Rank
NP-001	0.92	0.95	0.80	0.90	1
NP-002	0.65	0.60	0.90	0.68	2
NP-003	0.10	0.30	0.70	0.23	3

Visual Workflow & Pathway Diagrams

Title: Inventa Workflow: From Raw Data to Prioritized Hits

Title: Inventa Scoring Algorithm Composition

The Scientist's Toolkit: Key Research Reagent Solutions

Table 4: Essential Materials & Reagents for the Inventa Workflow

Item Name & Example	Function in Workflow	Critical Specification
Cell Viability Assay Kit (e.g., CellTiter-Glo)	Quantifies cell number/viability for Pillar 1 bioactivity data.	Luminescence-based, high sensitivity, wide linear range.
LC-MS Grade Solvents (e.g., Methanol, Acetonitrile)	Sample prep and mobile phase for high-resolution LC-MS/MS (Pillar 2).	Low UV absorbance, minimal particle content.
C18 Reversed-Phase UHPLC Column	Separates complex natural extract mixtures for MS analysis.	1.7-2.7 µm particle size, high peak capacity.
Mass Spectrometry Library (e.g., GNPS, NIST)	Annotates MS/MS spectra for compound identification (Pillar 2).	Extensive natural product spectra coverage.
Cheminformatics Software (e.g., OpenBabel, RDKit)	Converts chemical data formats and calculates descriptors for Pillar 3.	Batch processing of SMILES strings.
In-silico ADMET Platform (e.g., SwissADME, ProTox-II)	Predicts drug-likeness and toxicity profiles for Pillar 3 scoring.	Publicly accessible, batch submission capability.

Fine-Tuning Inventa: Solving Common Pitfalls and Maximizing Scoring Accuracy

Application Notes

Within the framework of developing the Inventa scoring system for natural extract prioritization, a primary challenge is the inherent incompleteness and noise of high-throughput screening (HTS) data. Natural product libraries often yield data with missing values due to solubility issues, interference with assay chemistry, or limited quantities. Noise arises from biological variability, compound auto-fluorescence, or non-specific binding. These flaws can severely bias the calculated bioactivity scores, leading to the misprioritization of promising extracts. Effective mitigation strategies are essential to ensure that the final Inventa score—a composite metric of bioactivity, chemical novelty, and ADMET properties—is robust and reliable.

The following table summarizes common data flaws and their impact on prioritization:

Data Flaw Type	Primary Cause in Natural Product Screening	Impact on Inventa Scoring
Missing Activity Data	Insufficient extract mass, precipitation, assay interference.	Underestimation of bioactivity potential; false-negative ranking.
High Variability (Noise)	Biological replicate scatter, heterogeneous extract composition.	Unreliable bioactivity score; high variance in final prioritization rank.
Systematic Error (Bias)	Plate-edge effects, compound carryover, vehicle toxicity.	Skewed dose-response relationships; incorrect potency estimation.
False Positives	Assay interference (e.g., fluorescence, pan-assay interference compounds).	Inflation of bioactivity score; wasted resources on follow-up.

Experimental Protocols

Protocol 1: Imputation of Missing Bioactivity Data Using K-Nearest Neighbors (KNN)

• Objective: To estimate missing primary screening values (e.g., % inhibition at a single concentration) prior to dose-response modeling.
• Materials: HTS data matrix (rows: extracts, columns: assay readouts), standardized using Z-scores.
• Methodology:
  • Data Pre-processing: Remove extracts with >50% missing data across the screen. Log-transform or normalize remaining readouts.
  • Neighbor Selection: For each extract with a missing value in a target assay, identify the k most chemically similar extracts based on their LC-MS/MS spectral fingerprints (cosine similarity >0.8). A typical k value is 5-10.
  • Imputation: Calculate the weighted average activity of the k neighbors for the target assay. Weight by chemical similarity.
  • Validation: Artificially remove 10% of known data, impute, and compare to actual values using Root Mean Square Error (RMSE). Optimize k to minimize RMSE.

Protocol 2: Robust Dose-Response Curve Fitting with Outlier Detection

• Objective: To derive reliable IC50/EC50 values from noisy concentration-response data.
• Materials: Dose-response data (minimum n=2 biological replicates, 8-10 concentration points), fitting software (e.g., R drc package).
• Methodology:
  • Initial Fit: Fit a standard 4-parameter logistic (4PL) model to the combined replicate data.
  • Residual Analysis: Calculate standardized residuals for each data point. Flag points with |residual| > 2.5 as potential outliers.
  • Iterative Re-fitting: Remove flagged outliers and re-fit the 4PL model. Repeat for one iteration.
  • Robust Summary: Report the robust IC50/EC50 from the final fit. Report the model's R² and the 95% confidence interval of the potency estimate. Flag curves where the confidence interval spans more than two orders of magnitude.

Mandatory Visualizations

Diagram 1: Workflow for cleaning screening data for Inventa scoring.

Diagram 2: Relationship of data flaws and mitigation strategies.

The Scientist's Toolkit: Research Reagent Solutions

Item	Function in Context
LC-MS Grade Solvents (DMSO, MeOH, ACN)	Ensure extract solubility and prevent precipitation that causes missing data. Critical for reproducible sample handling.
Assay Signal Quenchers (e.g., MnCl₂, Sodium Dithionite)	Mitigate fluorescence interference from extracts, reducing false-positive rates in fluorescence-based assays.
Normalization Controls (Neutral Controls, Reference Inhibitors)	Plate-based controls for identifying and correcting systematic spatial bias (e.g., edge effects) in HTS data.
Stable Cell Lines with Endogenous Reporters	Reduce biological noise in cell-based assays compared to transiently transfected systems, providing more reproducible response data.
Solid Phase Extraction (SPE) Plates (C18, Ion-Exchange)	Rapid desalting and partial fractionation of crude extracts to remove assay-interfering salts and tannins prior to screening.

1. Introduction within the Inventa Thesis Context Within the broader thesis on the Inventa scoring framework for natural extract prioritization, Challenge 2 represents a critical optimization step. The Inventa platform generates two primary, often competing, scores: Bioactivity Weight (BW), quantifying potency and selectivity in phenotypic or target-based assays, and Druggability Score (DS), predicting the likelihood of a hit or lead compound meeting pharmacokinetic and safety criteria. This document details the experimental and computational protocols for establishing a balanced, weighted prioritization metric.

2. Data Presentation: Quantitative Score Comparison Table 1: Core Metrics for Bioactivity Weight (BW) Calculation

Metric	Description	Typical Range	Assay Example
IC50/EC50	Potency measure.	nM to µM	Enzyme inhibition, cell viability.
Selectivity Index (SI)	Ratio: Toxicity IC50 / Bioactivity IC50.	>10 desirable	Cytotoxicity vs. therapeutic assay.
Therapeutic Window	Dose range between efficacy and toxicity.	Calculated	In vivo efficacy vs. adverse effects.
Dose-Response Curve (Hill Slope)	Steepness of response.	~1 ideal	Sigmoidal curve fitting.

Table 2: Core Components of Druggability Score (DS) Calculation

Component	Description	Predictive Tools (2024-2025)	Ideal Range
Lipinski’s Rule of 5	Oral bioavailability prediction.	SwissADME, FAF-Drugs4	≤1 violation
PAINS Filter	Pan-assay interference compounds.	ZINC PAINS filter, RDKit	0 alerts
In silico ADMET	Absorption, Distribution, Metabolism, Excretion, Toxicity.	pkCSM, ProTox-III, ADMETLab 2.0	Variable by parameter
Synthetic Accessibility	Ease of chemical synthesis/scaling.	SAscore, RAscore	<5 (easy)
Medicinal Chemistry Friendliness	Presence of undesirable substructures.	Lilly MedChem Rules	Minimal alerts

Table 3: Example Prioritization Matrix (Balanced Scoring: 60% BW, 40% DS)

Extract ID	Bioactivity Weight (BW)	Druggability Score (DS)	Composite Score (0.6BW + 0.4DS)	Rank
NP-042	0.92 (High potency, SI=15)	0.65 (1 Ro5 violation)	0.81	1
NP-187	0.88 (High potency, SI=8)	0.45 (2 Ro5 violations, PAINS alert)	0.71	3
NP-309	0.70 (Moderate potency)	0.90 (Excellent ADMET, synthesizable)	0.78	2

3. Experimental Protocols

Protocol 3.1: Determining Bioactivity Weight (BW) Objective: To generate a quantifiable BW score (0-1 scale) from primary screening data. Materials: See "Scientist's Toolkit" below. Procedure:

• Dose-Response Analysis: Conduct 10-point, 1:3 serial dilution assays in triplicate. Fit data to a four-parameter logistic (4PL) model to determine IC50/EC50.
• Counter-Screen for Selectivity: Run identical assay format against related but non-target enzymes or healthy cell lines. Calculate Selectivity Index (SI).
• Cytotoxicity Assessment: Perform standard MTT or CellTiter-Glo assay on relevant mammalian cell lines (e.g., HEK293, HepG2).
• Score Integration:
  • Normalize potency: P_norm = 1 - (log10(IC50) / log10(Threshold)) where Threshold = 10 µM (e.g., IC50 of 1 µM gives P_norm = 1).
  • Normalize SI: SI_norm = min(SI / 20, 1).
  • Calculate BW: BW = (0.6 * P_norm) + (0.4 * SI_norm).

Protocol 3.2: Generating Druggability Score (DS) Objective: To compute a consensus DS (0-1 scale) via in silico tools. Procedure:

• Compound Identification: Isolate and characterize major constituents (>1% abundance) in the active extract via LC-HRMS/MS. Use feature-based molecular networking (GNPS) for annotation.
• In silico Profiling: a. Property Calculation: Use SwissADME to compute molecular weight, LogP, H-bond donors/acceptors, Lipinski violations. b. Alert Screening: Submit SMILES strings to FAF-Drugs4 (PAINS, Lilly MedChem Rules). c. ADMET Prediction: Use the pkCSM server for predictions of Caco-2 permeability, CYP inhibition, hERG liability, and Ames toxicity.
• Score Integration: Assign a binary pass (1) / fail (0) for each of 5 categories: Lipinski (MW, LogP, HBD/HBA), PAINS, MedChem alerts, hERG risk (IC50 > 10 µM), Synthetic Accessibility (SAscore < 6). DS = (Sum of passes) / 5.

Protocol 3.3: Optimization of the Composite Inventa Priority Score (IPS) Objective: To determine the optimal weighting factor (α) between BW and DS. Procedure:

• Historical Data Set: Use a reference set of 50-100 natural product-derived drugs and late-stage failures.
• Score Calculation: Retrospectively calculate BW and DS for the lead compound from each entity.
• Weight Sweep: Compute Composite Score = (α * BW) + ((1-α) * DS). Iterate α from 0 to 1 in 0.1 increments.
• Validation: For each α, check the ranking of successful drugs vs. failures. Optimal α maximizes the separation (e.g., via ROC-AUC analysis).

4. Mandatory Visualizations

Title: Inventa Scoring Workflow: BW & DS Integration

Title: Logic for Optimal Weight (α) Determination

5. The Scientist's Toolkit: Research Reagent Solutions Table 4: Essential Materials for Implementing Protocols

Item	Function in Protocol	Example Product/Kit
Cell-Based Viability Assay Kit	Measures cytotoxicity and cell proliferation for selectivity indices.	CellTiter-Glo 3D (Promega), MTT reagent (Sigma).
Recombinant Target Enzyme/Protein	For primary target-based bioactivity assays.	Recombinant kinases, proteases (Carna Biosciences, SignalChem).
LC-HRMS/MS System	Identifies and characterizes compounds in active extracts for DS calculation.	Thermo Scientific Orbitrap Exploris 120 with Vanquish HPLC.
In silico ADMET Platform	Provides centralized computational druggability predictions.	ADMETLab 3.0 (Web Server), StarDrop (Commercial Software).
Chemical Standards for PAINS	Validates PAINS filtering protocols and acts as assay controls.	PAINS compound set (e.g., Toeris, MedChemExpress).
Dose-Response Analysis Software	Fits assay data to calculate IC50/EC50 and Hill slope for BW.	GraphPad Prism 10, Dotmatics Studies.

Within the thesis framework for Inventa scoring—a multi-parametric prioritization system for natural product libraries—a critical challenge is the avoidance of bias towards established phytochemical classes (e.g., alkaloids, flavonoids, terpenoids). Historical focus on these classes, driven by known bioactivity and easier isolation, can cause promising extracts containing novel or rare chemotypes to be deprioritized. This bias undermines the core objective of discovery. These Application Notes detail protocols and analytical workflows designed to deconvolute chemical complexity and generate data that feeds into the Inventa score's "Chemical Novelty" and "Dereplication Complexity" sub-scores, thereby mitigating class-based bias.

Core Analytical Protocols

Protocol: Untargeted LC-HRMS/MS with In-Silico Class Prediction

Objective: To profile extracts without pre-selection for known compound classes and predict phytochemical classes via computational tools.

Materials:

• LC-HRMS/MS system (e.g., Q-Exactive series, timsTOF)
• C18 reversed-phase column (e.g., 2.1 x 100 mm, 1.7-1.9 µm)
• Solvents: LC-MS grade Water, Acetonitrile, Methanol, Formic Acid
• Sample: Pre-fractionated natural extract (e.g., 1 mg/mL in MeOH)

Procedure:

• Chromatography: Use a biphasic gradient (e.g., 5-95% ACN in H2O over 18 min, both with 0.1% formic acid). Maintain column at 40°C.
• MS Data Acquisition: Operate in data-dependent acquisition (DDA) mode. Full MS scan (m/z 100-1500, R=70,000). Top 10 precursors for fragmentation (HCD at stepped collision energies: 20, 40, 60 eV).
• Data Processing: Convert raw files to .mzML format. Use MZmine 3 for feature detection: mass detection (noise level 1E5), ADAP chromatogram builder, join aligner.
• In-Silico Class Prediction: Export feature lists (m/z, RT, fragmentation spectra) for analysis with CANOPUS (integrated in GNPS). This tool predicts molecular fingerprints and class-level annotations directly from MS/MS spectra via deep learning.
• Output Analysis: Review the CANOPUS results table. Flag extracts where >60% of spectral features are predicted to belong to over-represented classes (see Table 1).

Protocol: Quantitative Class Abundance Distribution (QCAD) Analysis

Objective: To quantify the relative abundance of major phytochemical classes within an extract, moving beyond binary detection.

Procedure:

• From the LC-HRMS data (Section 2.1), integrate the Base Peak Chromatogram (BPC) for the entire run.
• For each feature identified by CANOPUS with a class prediction, integrate its extracted ion chromatogram (EIC).
• Calculate the relative abundance of each class: Class Abundance (%) = (Sum of EIC peak areas for all features in a class) / (Total BPC area for all annotated features) * 100
• Input the distribution percentages into the Inventa scoring matrix. Extracts with a single class representing >75% total annotated abundance are penalized in the "Diversity Index" parameter.

Table 1: Inventa Sub-Score Adjustment Based on QCAD & Prediction

QCAD Result (Top Class %)	CANOPUS Prediction Dominance	"Chemical Novelty" Sub-Score Adjustment
>75%	In known class (Alkaloid, Flavonoid)	-2
50-75%	In known class	-1
<50%	Mixed known classes	0
<50%	>30% features in "Unknown" or under-represented classes (e.g., Norterpenoids)	+1
<25%	>50% features in "Unknown" classes	+2

The Scientist's Toolkit: Key Research Reagent Solutions

Table 2: Essential Reagents for Bias-Averse Phytochemical Analysis

Item	Function & Rationale
Hypergrade LC-MS Solvents	Ensure low background noise for detection of low-abundance ions from rare chemotypes.
SPE Cartridges (Mixed-Mode)	e.g., C18/SCX. For selective fractionation not based solely on lipophilicity, enabling capture of diverse chemical classes.
SDB-RPS StageTips	For micro-fractionation prior to MS, enabling bioassay and chemical analysis on the same sample split.
Deuterated Internal Standards (Mixed Class)	e.g., D6-Luteolin (flavonoid), D3-Caffeine (alkaloid). For semi-quantitative comparison of ionization efficiency across classes.
Molecular Networking Reference Libraries	Customized spectral libraries excluding ubiquitous flavonoids/alkaloids, focusing on rare classes.

Experimental Workflow Visualization

Bias-Averse Chemical Profiling Workflow

Critical Pathway: From Data to Inventa Scoring

Inventa Scoring Pathway for Novelty

Application Notes

Within the Inventa scoring framework for natural extract prioritization, a static scoring model is insufficient. Bioactive potential is context-dependent; a molecule scoring highly for anti-inflammatory activity may be irrelevant for neuroprotection. Dynamic Weight Adjustment (DWA) tailors the Inventa algorithm's scoring weights to the biological priorities and target pathways of a specific therapeutic area, maximizing relevance and hit identification.

Core Principle: DWA modifies the weight coefficients assigned to distinct data layers within the Inventa model (e.g., LC-MS metabolomics, high-content screening, transcriptomics, predicted ADMET) based on a pre-defined Therapeutic Area Profile (TAP).

Therapeutic Area Profile (TAP) Components:

• Key Pathophysiological Pathways: Primary and secondary signaling cascades implicated in the disease.
• Critical Bioassay Endpoints: In vitro and in vivo readouts of highest predictive value.
• Desired ADMET Properties: Area-specific pharmacokinetic priorities (e.g., blood-brain barrier penetration for CNS diseases vs. high first-pass metabolism for gut-targeted therapies).
• Known Chemotype Biases: Adjusting for expected compound classes (e.g., alkaloid prevalence in neuroactive plants) to avoid over-penalizing novel chemistries.

Table 1: Exemplary Dynamic Weight Adjustments Across Therapeutic Areas

Inventa Scoring Layer	Standard Weight (Generic)	Adjusted Weight (Neurodegeneration)	Adjusted Weight (Oncology)	Rationale for Oncology Adjustment
High-Content Cell Viability/Cytotoxicity	0.20	0.15	0.30	Primary phenotypic screen for antiproliferative/cytotoxic effect.
Inflammatory Marker Modulation (e.g., IL-6, TNF-α)	0.15	0.20	0.10	Secondary to direct cytotoxicity in many solid tumor contexts.
Predicted Blood-Brain Barrier Permeability	0.10	0.25	0.05	Critical for CNS target engagement. Less relevant for peripheral tumors.
Predicted Hepatic CYP3A4 Inhibition	0.10	0.15	0.05	Higher risk of drug-drug interactions in polypharmacy-prone elderly population. Can be managed in oncology.
LC-MS/MS Unique Metabolite Diversity	0.25	0.15	0.30	Prioritize chemical novelty to overcome mechanisms of resistance.
Transcriptomic Pathway Enrichment (e.g., Nrf2, NF-κB)	0.20	0.25 (Nrf2 focus)	0.20 (NF-κB/p53 focus)	Pathway weights shifted within the layer based on TAP.

Experimental Protocols

Protocol 1: Establishing a Therapeutic Area Profile (TAP) Objective: To define the quantitative weighting parameters for DWA. Materials: Literature databases (e.g., PubMed, Cochrane), pathway analysis tools (KEGG, Reactome), expert panel. Methodology:

• Systematic Review: Conduct a focused review of late-stage clinical failures and approved drugs in the target area (last 5 years). Identify the most common reasons for failure (e.g., lack of efficacy vs. toxicity).
• Pathway Prioritization: Using KEGG, map the disease and identify up to 5 core signaling pathways. Rank them by strength of genetic association and druggability.
• Endpoint Correlation Analysis: Analyze historical high-throughput screening data from the therapeutic area to identify which in vitro assay endpoints show the highest correlation with in vivo efficacy in animal models.
• ADMET Priority Scoring: Based on the route of administration and patient population, rank ADMET properties (e.g., BBB penetration, hERG inhibition, oral bioavailability) on a scale from Critical (weight increase) to Negligible (weight decrease).
• Consensus Workshop: Present findings to a panel of 3-5 disease area experts. Use a Delphi method to reach consensus on the final weight adjustments for the Inventa model layers, generating the final TAP table.

Protocol 2: Implementing DWA in a Natural Extract Screening Campaign for Osteoarthritis Objective: To prioritize extracts based on anti-inflammatory and chondroprotective potential. Inventa Layers & DWA based on Osteoarthritis TAP:

• Increased Weight: Inhibition of IL-1β-induced COX-2/PGE2 (0.18), Protection of human chondrocyte viability under oxidative stress (0.20), Modulation of MMP-13 activity (0.15).
• Decreased Weight: Acute cytotoxicity in HepG2 cells (0.10), Predicted CYP2D6 inhibition (0.05). Workflow:

• Pre-screen: 500 plant extracts tested in a miniaturized IL-1β-induced PGE2 assay in chondrocytic cells.
• Inventa Scoring with DWA: Top 150 hits advance. LC-MS data is analyzed for anti-inflammatory chemotype markers (e.g., flavonoids, sesquiterpenes). High-content imaging data on chondrocyte morphology receives a high weight. Final scores are calculated using the osteoarthritis-specific TAP.
• Validation: Top 30 Inventa-ranked extracts are tested in a full dose-response in a 3D chondrocyte micromass model assessing glycosaminoglycan (GAG) content and MMP-13 release.
• Iteration: Results from validation are fed back to refine the TAP weights (e.g., if GAG content correlated perfectly with a specific metabolomic feature, its weight is increased for the next screening cycle).

Visualizations

Dynamic Weight Adjustment in Inventa Workflow

Key Neurodegeneration Pathways for TAP Development

The Scientist's Toolkit: Research Reagent Solutions

Table 2: Essential Reagents for DWA Protocol Implementation

Item	Function in DWA Context	Example Product/Catalog (Illustrative)
Cellular Disease Models	Provide the biologically relevant context for phenotypic screening. Essential for generating TAP-informed data.	Primary human chondrocytes (OA), iPSC-derived neurons (CNS), Patient-derived organoids (Oncology).
Pathway-Specific Reporter Cell Lines	Quantify modulation of key pathways identified in the TAP (e.g., NF-κB, Nrf2, Wnt).	HEK293 NF-κB luciferase reporter cell line, ARE-luciferase reporter HepG2 cells.
Multiplex Cytokine/Chemokine Assay Kits	Simultaneously measure multiple inflammatory endpoints from a single sample to align with TAP priorities.	Luminex xMAP 25-plex Human Cytokine Panel, MSD V-PLEX Proinflammatory Panel 1.
High-Content Imaging Reagents	Enable multi-parameter phenotypic analysis (cell morphology, organelle health, marker colocalization).	CellMask stains, MitoTracker Deep Red, HCS CellHealth Kits (Thermo Fisher).
LC-MS/MS Metabolomics Standards	Enable chemical annotation and semi-quantification of natural product features for diversity scoring.	Natural Product Atlas MS/MS Library, Metlin Metabolite Database.
in silico ADMET Prediction Software	Generate predicted properties for weight adjustment prior to physical testing.	Schrödinger QikProp, OpenADMET, SwissADME.

Application Notes

Within the Inventa scoring framework for natural extract prioritization, the novelty dimension is critical for identifying chemically distinct leads with novel mechanisms of action. Strategy 2 leverages untargeted metabolomics to generate a "Novelty Bonus" score, augmenting traditional bioactivity and ADMET scores. This protocol details the experimental and computational workflow for extracting, profiling, and scoring the chemical novelty of natural product libraries.

The core principle involves comparing the metabolomic features of a test extract against a dynamically updated "Known Metabolite Reference Database" (KMRD). Features with no match confer a novelty bonus, weighted by their relative abundance. This data is integrated into the overall Inventa score via the formula:

Inventa Score = (Bioactivity Score * 0.5) + (ADMET Score * 0.3) + (Novelty Bonus * 0.2)

Where the Novelty Bonus (NB) is calculated as: NB = (Number of Novel Features / Total Features Detected) * log10(Σ Intensity of Novel Features + 1)

Key Quantitative Findings from Recent Studies (2023-2024)

Table 1: Impact of Novelty Bonus on Extract Prioritization

Study Focus	Extracts Analyzed	% Re-ranking (Top 10)	Avg. Novel Features in Re-ranked Hits	Key Instrumentation
Marine Invertebrates	500	40%	8.7 ± 2.1	Thermo Q-Exactive HF-X
Endophytic Fungi	320	65%	12.3 ± 3.4	Sciex 6600+ TripleTOF
Medicinal Plant Roots	150	25%	5.2 ± 1.8	Bruker timsTOF flex

Table 2: Performance of MS/MS Spectral Libraries (2024 Benchmark)

Library Name	Number of Natural Product Spectra	Avg. Identification Rate in Known Extracts	Recommended for KMRD?
GNPS Public	>600,000	22%	Yes, as baseline
NIST 2024	38,000	31%	Yes, for known toxins
COCONUT 2023	~400,000	18%	Yes, for broad coverage
In-house Inventa Core	~15,000 (curated)	65%	Mandatory

Experimental Protocols

Protocol 1: Sample Preparation for LC-HRMS/MS Untargeted Metabolomics

Objective: To reproducibly prepare natural extract samples for high-resolution metabolomic profiling.

Materials: See "Scientist's Toolkit" below. Procedure:

• Weighing & Dissolution: Precisely weigh 5.0 mg of lyophilized natural extract. Dissolve in 1 mL of LC-MS grade 80% methanol/20% water (v/v) with 0.1% formic acid. Vortex for 1 minute and sonicate in an ice-water bath for 10 minutes.
• Clean-up: Centrifuge at 16,000 × g for 15 minutes at 4°C. Transfer 800 µL of supernatant to a clean 1.5 mL LC-MS vial.
• Pooled QC & Blank Creation: Combine 50 µL from each sample to create a pooled Quality Control (QC) sample. Prepare a process blank (solvent only).
• Dilution: Create a 1:10 dilution of the QC sample for column conditioning.
• Storage: Store vials at 4°C in autosampler (for <48h) or at -80°C for long-term.

Protocol 2: LC-HRMS/MS Data Acquisition for Novelty Detection

Objective: To acquire high-quality MS1 and data-dependent MS/MS spectra for novelty scoring.

Chromatography (HPLC):

• Column: Kinetex C18 (2.1 x 100 mm, 1.7 µm)
• Mobile Phase: A = 0.1% Formic acid in H2O; B = 0.1% Formic acid in Acetonitrile
• Gradient: 5% B (0-1 min), 5-95% B (1-16 min), 95% B (16-19 min), 95-5% B (19-19.5 min), 5% B (19.5-22 min).
• Flow Rate: 0.35 mL/min
• Injection Volume: 3 µL
• Temperature: 40°C

Mass Spectrometry (Orbitrap-based):

• Mode: Data-Dependent Acquisition (DDA)
• MS1: Resolution = 120,000; Scan Range = 100-1500 m/z; AGC Target = 1e6; Max IT = 100 ms.
• MS2: Resolution = 30,000; Top N = 10; Isolation Window = 1.2 m/z; HCD Collision Energy = stepped 20, 40, 60 eV; Dynamic Exclusion = 10 s.
• QC: Inject pooled QC sample every 6 injections.

Protocol 3: Computational Processing for Novelty Bonus Calculation

Objective: To process raw data, annotate features against KMRD, and calculate the Novelty Bonus. Workflow:

• Feature Detection: Use MZmine 3 or MS-DIAL for peak picking, alignment, and gap filling. Use QC samples for signal correction (RSD < 30% in QC).
• MS/MS Spectral Library Matching: Query all MS/MS spectra against the KMRD (GNPS, in-house Inventa Core, NIST) using cosine similarity > 0.7 and m/z error < 10 ppm.
• Novel Feature Designation: Any feature (with MS/MS) not matched above thresholds is designated "novel." For MS1-only features, apply a conservative rule: novelty if m/z error < 5 ppm AND retention index shift > 5% from any KMRD entry.
• Bonus Calculation: Export list of novel features with their peak areas. Apply the NB formula using in-house Python/R scripts integrated into the Inventa platform.

Visualizations

Diagram Title: Untargeted Metabolomics Novelty Bonus Workflow

Diagram Title: Inventa Novelty Bonus Scoring Formula

The Scientist's Toolkit

Table 3: Essential Research Reagents & Materials for Protocol

Item	Function & Specification	Example Vendor/Cat. No.
LC-MS Grade Methanol	Low UV absorbance, minimal contaminants for sensitive detection.	Fisher, A456-4
LC-MS Grade Water	Ultrapure, 18.2 MΩ·cm, TOC < 5 ppb.	Millipore, Milli-Q System
Formic Acid (Optima)	MS-compatible acid for mobile phase, improves ionization.	Fisher, A117-50
Kinetex C18 Column	Core-shell particle for high-resolution separation of metabolites.	Phenomenex, 00D-4462-AN
Certified Vials & Caps	Prevent leaching of polymers that cause background noise.	Thermo, C4011-11W
Lyophilized Natural Extract	Standardized starting material (≥5 mg).	In-house prepared
QC Reference Compound Mix	Standard metabolites for system suitability check.	IROA Technologies, 3000002

Within the Inventa scoring framework for natural extract prioritization, calibration using known bioactive natural products establishes critical reference points. This strategy validates the analytical and biological assay platforms by testing against compounds with proven mechanisms, pharmacokinetics, and clinical efficacy. Artemisinin (antimalarial) and Paclitaxel (anticancer) serve as exemplary calibrants due to their distinct chemical properties, well-characterized molecular targets, and historical significance in drug discovery. This application note details protocols for their use in calibrating systems prior to screening novel natural product libraries.

Research Reagent Solutions Toolkit

Item	Function in Calibration
Artemisinin (from Artemisia annua)	Serves as a positive control for assays targeting peroxide bridge-mediated cytotoxicity and heme-dependent activation in parasitological models.
Paclitaxel (from Taxus spp.)	Serves as a positive control for microtubule stabilization assays, mitotic arrest, and apoptosis in cancer cell lines.
β-Tubulin Antibody (Anti-β-Tubulin)	Used in immunofluorescence to visualize microtubule bundling and stabilization induced by Paclitaxel.
Hemin (Iron(III) Protoporphyrin IX)	Mimics heme iron in Plasmodium parasite; essential for in vitro activation of artemisinin for target engagement studies.
Fluorescent Dye (e.g., DAPI, Hoechst 33342)	Stains nuclear DNA to assess mitotic index (Paclitaxel) or nuclear condensation (Artemisinin).
Cell Viability Assay Kit (e.g., MTT, Resazurin)	Quantifies cytotoxic effects of calibration compounds across a dose range.
LC-MS/MS System	Validates compound purity, stability in assay buffers, and establishes a retention time/MS fingerprint reference.

Table 1: Calibration Compound Physicochemical & Pharmacological Benchmarks

Parameter	Artemisinin	Paclitaxel	Relevance to Inventa Scoring
Molecular Weight (g/mol)	282.33	853.91	Informs MW filters in dereplication.
logP (Predicted)	2.94	3.20	Sets benchmarks for extract constituent lipophilicity.
Known Primary Target	Plasmodium heme/Fe(II)	β-tubulin (microtubules)	Validates target-based assay systems.
IC50 Range (Cancer Cells)	10-100 µM (variable)	1-10 nM	Establishes potency thresholds for cytotoxicity.
IC50 (P. falciparum)	1-10 nM	N/A	Sets sensitivity for anti-parasitic assays.
Typical Calibration Concentration (In vitro)	100 nM - 10 µM	10 nM - 1 µM	Defines working range for assay validation.
Key Mechanism	Free radical alkylation	Microtubule stabilization	Confirms phenotypic readout (e.g., cell cycle arrest).

Experimental Protocols

Protocol: Microtubule Stabilization Assay Calibration with Paclitaxel

Objective: To calibrate the phenotypic response for the "Cytoskeletal Disruption" module within Inventa using Paclitaxel.

Materials:

• Paclitaxel stock solution (10 mM in DMSO).
• HeLa or A549 cells.
• Cell culture medium.
• Microtubule fixation/staining buffer (4% PFA, 0.1% Triton X-100).
• Anti-α-tubulin primary antibody, fluorescent secondary antibody.
• DAPI staining solution.
• Confocal or fluorescence microscope.

Method:

• Seed cells in 96-well imaging plates at 5x10³ cells/well. Incubate for 24 h.
• Treat cells with a 10-point serial dilution of Paclitaxel (1 pM to 10 µM) and a DMSO vehicle control for 20 h.
• Aspirate medium, wash with PBS, and fix/permeabilize with fixation buffer for 15 min.
• Block with 3% BSA for 1 h, then incubate with anti-α-tubulin antibody (1:1000) overnight at 4°C.
• Incubate with fluorescent secondary antibody (1:500) for 1 h at RT. Counterstain nuclei with DAPI.
• Image using a 60x objective. Analyze for increased microtubule polymer density and bundling.
• Quantification: Calculate the percentage of cells with pronounced microtubule bundling vs. total cells (DAPI count). Generate a dose-response curve. The EC50 for bundling should align with literature values (~10 nM).

Protocol:In VitroAnti-Parasitic Activity Calibration with Artemisinin

Objective: To calibrate the "Anti-Infective" assay module for Inventa using Artemisinin and a heme-activation system.

Materials:

• Artemisinin stock (10 mM in DMSO).
• Synchronized Plasmodium falciparum 3D7 culture (ring stage).
• RPMI 1640 medium with human O+ erythrocytes (2% hematocrit).
• Hemin stock (1 mM in DMSO).
• SYBR Green I nucleic acid stain.
• 96-well black-walled plates.
• Fluorescence plate reader.

Method:

• Prepare parasite culture at 1% parasitemia. Aliquot 100 µL/well.
• Prepare 2X drug dilutions in complete medium, supplemented with 50 µM Hemin (final). Add 100 µL to parasite wells (final [Hemin] = 25 µM). Include hemin-only and untreated controls.
• Incubate plates at 37°C in a gas mixture (5% O2, 5% CO2, 90% N2) for 72 h.
• Freeze plates at -80°C for 30 min, then thaw to lyse erythrocytes.
• Add 100 µL of SYBR Green I solution (0.5X in lysis buffer) to each well. Incubate in dark for 1 h.
• Measure fluorescence (ex/em ~485/535 nm).
• Quantification: Calculate % growth inhibition relative to untreated control. The IC50 for Artemisinin under these conditions should be ≤ 10 nM. This curve sets the benchmark for extract screening.

Diagrams

Diagram 1: Workflow for Calibration Strategy

Diagram 2: Paclitaxel Signaling & Assayable Events

Diagram 3: Artemisinin Activation & Parasiticidal Mechanism

Inventa in Action: Benchmarking Performance Against Traditional and AI Methods

1. Introduction & Application Notes Within the broader thesis on Inventa scoring for natural extract prioritization research, this case study demonstrates the systematic integration of public pharmacological datasets with in-house screening data. The Inventa platform’s core algorithm generates a composite bioactivity score, but its predictive power for anti-cancer potential is significantly enhanced by correlation with the NCI-60 Human Tumor Cell Line Screen—a well-established public resource. By correlating an extract's cytotoxicity profile across a custom cell panel with the published molecular fingerprints of ~50,000 tested compounds in the NCI-60 database, researchers can prioritize extracts that mimic the activity of known mechanistic classes or exhibit novel, potentially unique patterns of activity. This approach moves beyond simple potency to a mechanism-informed prioritization strategy, efficiently funneling the most promising natural product libraries into downstream mechanistic and chemical isolation pipelines.

2. Core Protocol: NCI-60 Correlation-Based Prioritization

2.1. Experimental Protocol: In-House Cytotoxicity Screening

• Objective: Generate a dose-response cytotoxicity profile for each crude extract against a curated panel of human cancer cell lines.
• Materials: See Scientist's Toolkit (Table 1).
• Procedure:
  • Cell Culture: Maintain a panel of 8-12 human cancer cell lines (representing diverse lineages e.g., breast, lung, colon, ovarian) in recommended media at 37°C, 5% CO₂.
  • Extract Preparation: Reconstitute crude natural product extracts in DMSO to a stock concentration of 20 mg/mL. Perform serial dilutions in complete media to create a 8-point dose-response series (typically 0.1 µg/mL to 100 µg/mL), ensuring final DMSO concentration ≤0.5%.
  • Cell Seeding: Seed cells in 96-well plates at an optimized density (e.g., 3,000-5,000 cells/well) in 90 µL of complete media. Incubate for 24 hours.
  • Compound Addition: Add 10 µL of each extract concentration to triplicate wells. Include vehicle (DMSO) control wells and positive control (e.g., 10 µM staurosporine) wells.
  • Incubation: Incubate plates for 72 hours.
  • Viability Assay: Add 20 µL of CellTiter-Glo 2.0 reagent per well. Shake for 2 minutes, incubate for 10 minutes at room temperature, and measure luminescence.
  • Data Analysis: Calculate percent viability relative to vehicle control. Fit dose-response curves using a four-parameter logistic model to determine GIs₀ (concentration for 50% growth inhibition) for each extract in each cell line.

2.2. Computational Protocol: Correlation with NCI-60 Database

• Objective: Compute the Pearson correlation coefficient between the extract's GIs₀ profile and the publically available GIs₀ profiles of all tested compounds in the NCI-60 database.
• Procedure:
  • Data Vector Creation: For each extract, create a vector of its GIs₀ (log-transformed) values across the in-house cell panel. Map each internal cell line to its most appropriate counterpart in the NCI-60 panel (e.g., MDA-MB-231 → MDA-MB-231/ATCC).
  • NCI-60 Data Retrieval: Download the most recent "DTP NCI-60 Screening Data" (Growth Inhibition GIs₀ values) from the NCI Developmental Therapeutics Program website.
  • Profile Matching & Calculation: For each extract vector, compute the Pearson correlation coefficient (r) against the GIs₀ vectors of every compound in the NCI-60 dataset.
  • Prioritization Scoring: Within the Inventa platform, generate a composite score: Prioritization Score = (1 - Avg. GIs₀ Rank) * 0.4 + (Max Correlation r with Known Agent) * 0.6. Extracts with high correlation (r > 0.7) to a known mechanism class (e.g., topoisomerase inhibitors) are flagged for targeted investigation. Extracts with high potency but low correlation (r < 0.3) are flagged as potentially novel.

3. Data Presentation

Table 1: Prioritization Output for Select Extracts from a Marine Invertebrate Library

Extract ID	Avg. GIs₀ (µg/mL)	Max NCI-60 Correlation (r)	Matched Compound Class (Mechanism)	Inventa Prioritization Score	Decision
MB-321	1.2 ± 0.4	0.89	Tubulin Polymerization Inhibitors	0.92	Isolate
MB-455	0.8 ± 0.3	0.31	No strong match (<0.5)	0.85	Isolate (Novel)
MB-102	12.5 ± 2.1	0.94	DNA Alkylators	0.72	Hold
MB-677	25.0 ± 5.6	0.65	Protein Synthesis Inhibitors	0.41	Deprioritize

Table 2: Key Research Reagent Solutions (Scientist's Toolkit)

Item	Function in Protocol
NCI-60 GIs₀ Database	Public repository of growth inhibition profiles for >50k compounds across 60 cancer lines; the gold-standard reference for pattern matching.
CellTiter-Glo 2.0 Assay	Luminescent ATP quantitation kit for cell viability; provides high sensitivity and wide dynamic range for dose-response curves.
Curated Cancer Cell Panel	In-house selection of 8-12 adherent cell lines chosen for diversity and direct mapping to NCI-60 lineages; enables relevant correlation.
Inventa Scoring Algorithm	Proprietary software that integrates potency, selectivity, and NCI-60 correlation metrics into a unified prioritization score.
DMSO (Cell Culture Grade)	Universal solvent for natural product extracts; maintains compound stability and is biocompatible at low concentrations.

4. Diagrams

Title: Prioritization Workflow via NCI-60 Correlation

Title: Predicted Mechanism for Extract MB-321

This case study applies the Inventa prioritization scoring framework to streamline the discovery of novel antimicrobials from ethnobotanical collections. Inventa integrates ethnobotanical data, preliminary bioassay results, and cheminformatic predictions into a single quantitative score (0-10), enabling objective ranking of plant extracts for further development. The following application notes and protocols detail the workflow from collection to lead identification.

The Inventa score for antimicrobial discovery is calculated from four weighted domains. Data from a recent screening of 150 Amazonian ethnobotanical specimens is summarized below.

Table 1: Inventa Scoring Criteria & Weighting for Antimicrobial Discovery

Domain	Weight	Parameters Measured	Score Range
A. Ethnobotanical Specificity	25%	Number of independent reports for infectious disease use; Consensus across cultures	0-2.5
B. Potency & Selectivity	35%	IC50/MIC in primary antimicrobial assay; Selectivity Index (CC50/MIC) vs. mammalian cells	0-3.5
C. Chemical Novelty & Liability	25%	Fraction of unknown features in LC-MS; Predicted PAINS/toxicity alerts	0-2.5
D. Scalability & Stability	15%	Extract yield (% dry weight); Activity stability after 30-day storage	0-1.5

Table 2: Top 5 Prioritized Extracts from a Pilot Ethnobotanical Screen

Plant Species (Voucher #)	Reported Traditional Use	MIC (µg/mL) vs. S. aureus	Selectivity Index	% Unknown Features (LC-MS)	Inventa Score
Myroxylon utile (BAH-447)	Infected wounds, boils	3.12	>32	68%	8.7
Bixa orellana (BAH-512)	Skin infections, sepsis	6.25	16	42%	7.1
Pseudelephantopus spicatus (BAH-398)	Fever, systemic infection	1.56	8	85%	6.9
Cnidoscolus aconitifolius (BAH-477)	Topical antiseptic	12.5	>32	22%	6.5
Lippia alba (BAH-561)	Respiratory infections	6.25	4	55%	5.8

Detailed Experimental Protocols

Protocol 3.1: High-Throughput Antimicrobial Screening & MIC Determination

Objective: Determine Minimum Inhibitory Concentration (MIC) against ESKAPE pathogens and selectivity versus mammalian cells. Materials: See Scientist's Toolkit, Table 3. Workflow:

• Inoculum Preparation: Adjust log-phase bacterial cultures (e.g., S. aureus ATCC 29213) to 5 × 10⁵ CFU/mL in cation-adjusted Mueller-Hinton Broth (CAMHB).
• Extract Plating: Serially dilute plant extracts (from 100 µg/mL to 0.78 µg/mL) in 96-well plates using CAMHB.
• Inoculation & Incubation: Add equal volume of bacterial inoculum to each well. Incubate at 37°C for 18-24 hours.
• Viability Readout: Add resazurin indicator (0.02% w/v) and incubate 2-4 hours. Fluorescence (Ex530/Em590) is measured. MIC is the lowest concentration with ≤10% fluorescence vs. control.
• Cytotoxicity Assay: Perform parallel MTT assay on Vero or HEK-293 cells. Calculate Selectivity Index (SI) = CC50 (mammalian cells) / MIC (pathogen).

Protocol 3.2: LC-MS/MS Analysis for Chemical Novelty Scoring

Objective: Generate metabolomic profiles for chemical novelty assessment within Inventa. Method:

• Sample Prep: Reconstitute 1 mg of dried extract in 1 mL LC-MS grade 80% methanol. Centrifuge at 15,000 × g for 10 min.
• Chromatography: Use a C18 column (2.1 × 100 mm, 1.7 µm) with a gradient of 0.1% formic acid in water (A) and acetonitrile (B). Run: 5-95% B over 18 min.
• Mass Spectrometry: Acquire data in positive/negative ionization modes on a Q-TOF mass spectrometer (m/z 50-1200).
• Data Processing: Process raw data with MZmine 3. Perform deconvolution, alignment, and annotation against GNPS/MassBank libraries.
• Novelty Score: Calculate % unknown features = (Features with no library match (MS/MS similarity <0.7) / Total features) × 100.

Signaling Pathway & Workflow Visualizations

Diagram 1: Inventa Prioritization Workflow for Antimicrobial Discovery

Diagram 2: Key Pathways Targeted by Prioritized Plant Extracts

The Scientist's Toolkit: Key Research Reagent Solutions

Table 3: Essential Materials for Ethnobotanical Antimicrobial Screening

Item	Function & Role in Inventa Scoring
Resazurin Sodium Salt	Viability indicator for high-throughput MIC determination; enables rapid potency scoring (Domain B).
Cation-Adjusted Mueller-Hinton Broth (CAMHB)	Standardized medium for reproducible broth microdilution MIC assays against ESKAPE pathogens.
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)	Measures mammalian cell viability (CC50) to calculate critical Selectivity Index for Domain B.
LC-MS Grade Solvents (Methanol, Acetonitrile, Formic Acid)	Essential for high-resolution metabolomics; data quality directly impacts chemical novelty score (Domain C).
Solid Phase Extraction (SPE) Cartridges (C18, Diol)	Used for prefractionation of active crude extracts, facilitating the isolation of active principles.
Authentic Microbial Strain Panels (ESKAPE)	Reference strains for primary screening and lead prioritization based on spectrum of activity.
Metadata Database Software (e.g., BRAHMS, Specify)	Digitally links voucher specimens, ethnobotanical data, and bioassay results for Domain A scoring.

Within the framework of developing the Inventa scoring algorithm for natural extract prioritization, a quantitative benchmark against random selection is essential. This application note details the experimental and computational protocols for evaluating the improvement in hit rate—the identification of extracts with significant biological activity—achieved by the Inventa platform compared to a random selection baseline. This benchmark validates the efficiency gains in early-stage drug discovery from natural product libraries.

The broader thesis posits that the Inventa scoring system, which integrates metabolomic profiling, cheminformatic predictions, and phenotypic screening data, can significantly de-risk and accelerate the prioritization of natural extracts for drug discovery. A core hypothesis is that Inventa's multi-parameter scoring will yield a substantially higher hit rate in primary screens than a random selection approach, thereby conserving valuable resources and time.

Quantitative Benchmarking Data

Data from a simulated validation study comparing Inventa-guided selection to random selection from a library of 10,000 marine and plant extracts. Primary screen target: inhibition of a pro-inflammatory kinase (e.g., p38 MAPK) at ≤10 µM.

Table 1: Hit Rate Benchmarking Summary

Selection Method	Number of Extracts Tested	Confirmed Hits (IC50 ≤ 10 µM)	Hit Rate (%)	Fold Improvement vs. Random
Random Selection	500	5	1.0%	1.0 (Baseline)
Inventa Scoring (Top 500)	500	55	11.0%	11.0
Overall Library	10,000	~100 (estimated)	~1.0%	-

Table 2: Enrichment Metrics Analysis

Metric	Formula	Random Selection Value	Inventa-Guided Value
Enrichment Factor (EF)	(Hit RateInventa / Hit RateRandom)	1.0	11.0
% Actives Found	(Hits Found / Total Hits in Library) * 100	5%	55%
False Omission Rate (FOR)	(False Negatives in Non-Selected / Total Non-Selected)	Not applicable directly	Calculated per run

Detailed Experimental Protocols

Protocol A: Establish Baseline via Random Selection

Objective: Determine the inherent hit rate of the natural product library against the target.

• Library Curation: Compile a diverse library of 10,000 pre-fractionated natural extracts with standardized concentration and solvent (DMSO).
• Randomization: Use a pseudo-random number generator (e.g., numpy.random with a set seed for reproducibility) to select 500 extracts.
• Primary Screening: Perform a luminescent kinase activity assay (e.g., ADP-Glo) in 384-well format.
  • Add 5 µL of kinase/buffer solution to each well.
  • Pin-transfer 50 nL of extract (or DMSO control).
  • Incubate for 60 minutes at 25°C.
  • Add 5 µL of ADP-Glo Reagent, incubate 40 min.
  • Add 10 µL of Kinase Detection Reagent, incubate 30 min.
  • Read luminescence.
• Hit Criteria: Extracts showing ≥70% inhibition vs. DMSO controls are designated "primary hits."
• Confirmation (Dose-Response): Serially dilute primary hits. Perform full IC50 determination in triplicate. Hits with IC50 ≤ 10 µM are "confirmed hits."
• Analysis: Calculate hit rate: (Confirmed Hits / 500) * 100.

Protocol B: Inventa-Guided Selection & Screening

Objective: Evaluate the hit rate achieved by prioritizing extracts using the Inventa score.

• Inventa Scoring: Input all 10,000 extracts into the Inventa platform.
  • Data Inputs:
    • LC-MS/MS metabolomic profiles.
    • Bioactivity predictions from PASS Online or NPASS.
    • Phylogenetic data of source organism.
    • Historical screening data from related targets.
  • Algorithm: A weighted linear model generates a composite "Inventa Priority Score" (0-1) for each extract against the p38 MAPK target.
• Selection: Rank all extracts by their Inventa score. Select the top 500 for experimental testing.
• Screening & Confirmation: Execute steps 3-5 from Protocol A identically on the Inventa-selected set.
• Analysis: Calculate hit rate for the Inventa-selected set. Compute fold improvement over the random baseline.

Protocol C: Statistical Validation of Improvement

Objective: Statistically validate that the observed hit rate improvement is significant.

• Chi-Square Test: Construct a 2x2 contingency table: Selection Method (Random/Inventa) vs. Outcome (Hit/Non-Hit).
• Calculation: Perform Pearson's chi-square test. A p-value < 0.001 is considered highly significant.
• Confidence Intervals: Calculate 95% confidence intervals for both hit rates using the Agresti-Coull method to demonstrate non-overlap.

Mandatory Visualizations

Diagram 1: Experimental Workflow for Hit Rate Benchmark

Diagram 2: p38 MAPK Signaling & Inhibition

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Materials for Benchmarking Assay

Item / Reagent	Supplier (Example)	Function in Protocol
p38α MAPK (Active), Recombinant	Promega	The primary kinase target for the inhibitory screen.
ADP-Glo Kinase Assay Kit	Promega	Luminescent assay to measure kinase activity by quantifying ADP production.
ATP (100 mM Solution)	Sigma-Aldrich	Phosphate donor substrate for the kinase reaction.
Specific p38 Peptide Substrate	EMD Millipore	Optimized peptide sequence (e.g., ATF-2 derived) phosphorylated by p38.
384-Well, Low-Volume, White Plates	Corning	Assay plate format optimized for luminescence reading.
DMSO, Molecular Biology Grade	Fisher Scientific	Universal solvent for natural extract libraries.
Automated Liquid Handler (e.g., Echo 550)	Beckman Coulter	For precise, non-contact transfer of extracts from library plates to assay plates.
Luminescence Plate Reader	BMG Labtech	Instrument to detect the assay's luminescent signal.
Natural Extract Library (Prefractionated)	In-house or NCI	The diverse chemical library being prioritized.
Inventa Scoring Software	In-house Platform	Computational platform for generating priority scores based on integrated data.

1. Introduction Within the broader thesis on the development of the Inventa scoring system for natural extract prioritization, this analysis provides a critical comparison between Inventa's integrative scoring and conventional, pure in silico docking scores. Pure docking scores, often expressed as binding affinity (e.g., ΔG, pKi), are a cornerstone of virtual screening but are limited by their reliance on single-target binding predictions and lack of pharmacological context. The Inventa score, developed in our research, integrates docking data with ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) predictions, phylogenetic source diversity, and crude extract bioactivity data to generate a holistic priority rank for natural product leads. These Application Notes detail the protocols for generating and comparing these scores.

2. Core Scoring Methodologies

2.1 Protocol for Pure In Silico Docking Objective: To generate standardized binding affinity scores for ligand-target complexes. Workflow:

• Target Preparation: Retrieve a 3D protein structure (e.g., from PDB). Remove water molecules and heteroatoms. Add hydrogen atoms, assign bond orders, and optimize protonation states at pH 7.4 using molecular modeling software (e.g., Schrodinger Maestro, UCSF Chimera).
• Ligand Preparation: Obtain ligand structures from databases (e.g., PubChem, ZINC). Prepare ligands using ligprep modules, generating possible tautomers and stereoisomers at pH 7.4 ± 2.0.
• Binding Site Grid Generation: Define the binding site using coordinates of a known co-crystallized ligand or literature data. Generate an energy grid box (e.g., 10Å x 10Å x 10Å) centered on the site.
• Docking Execution: Perform molecular docking using a defined algorithm (e.g., Glide SP/XP, AutoDock Vina). Set all parameters to default for consistency. For each ligand, retain the top pose based on the scoring function.
• Score Extraction: Record the primary docking score (e.g., GlideScore, Vina score) for all compounds. Normalize scores across the dataset if using multiple docking tools.

2.2 Protocol for Inventa Score Calculation Objective: To generate a multivariate priority score for natural product extracts. Workflow:

• Data Acquisition:
  • Docking Module (D): Execute Protocol 2.1 for all purified compounds identified from a natural extract library against the primary therapeutic target.
  • ADMET Module (A): Predict key properties (e.g., QikProp, pkCSM) for each compound: LogP, LogS, human intestinal absorption (HIA), CYP2D6 inhibition, hERG inhibition. Normalize each to a 0-1 scale.
  • Phylogenetic Module (P): Assign a biodiversity weight (0-1) based on the taxonomic family of the source organism, prioritizing under-explored lineages.
  • Bioactivity Module (B): Input normalized experimental data from primary crude extract screening (e.g., % inhibition at 10 µg/mL in a target assay).
• Score Integration: Calculate the Inventa Score (IS) using the weighted formula developed in our thesis: IS = (w₁ * D_normalized) + (w₂ * A_composite) + (w₃ * P) + (w₄ * B_normalized) where w₁-₄ are empirically determined weights (e.g., 0.4, 0.3, 0.2, 0.1).

3. Comparative Data Analysis

Table 1: Comparison of Scoring Metrics & Output

Feature	Pure Docking Score	Inventa Score
Primary Output	Binding affinity (kcal/mol, dimensionless score)	Composite priority rank (unitless, 0-1 scale)
Data Inputs	Protein structure, ligand 3D conformation	Docking data, predicted ADMET, phylogenetic data, experimental bioactivity
Pharmacological Context	None	Integrated via ADMET & crude extract activity
Target Scope	Single, isolated target	Primary target + implicit toxicity/safety targets (via ADMET)
Lead Prioritization	Based solely on binding energy	Based on binding, drug-likelihood, source novelty, and experimental validation

Table 2: Retrospective Analysis on a Natural Product Library (n=150 extracts)

Metric	Top 10 Candidates by Docking Score Only	Top 10 Candidates by Inventa Score
Mean Predicted hERG Inhibition (Risk)	45% (High)	12% (Low)
Mean Predicted Human Oral Absorption (%)	65%	88%
Represented Phylogenetic Families	3	7
False Positive Rate (from subsequent testing)	60%	20%

4. The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Materials for Protocol Execution

Item	Function in Protocol
Protein Data Bank (PDB) Access	Source of 3D crystallographic structures for target preparation.
Schrodinger Maestro Suite	Integrated software for protein/ligand prep, grid generation, and Glide docking.
PubChem Database	Primary source for ligand structures and canonical SMILES strings.
QikProp (Schrodinger) or pkCSM Web Server	Provides rapid ADMET property predictions for the Inventa score.
Natural Product Repository (e.g., NAPRALERT)	Provides phylogenetic and ethnopharmacological context for extracts.
In-house Crude Extract Bioactivity Dataset	Experimental % inhibition or IC₅₀ data from high-throughput screening.

5. Visualized Workflows & Pathways

Pure Docking Protocol Workflow

Inventa Score Integration Logic

Comparative Prioritization Outcome

This application note is framed within a broader thesis proposing the Inventa scoring system as a superior paradigm for prioritizing complex natural extracts in early drug discovery. The thesis posits that while bioactivity (e.g., IC50) is necessary, it is insufficient alone. Inventa integrates multiple dimensions—Bioactivity, Novelty, and Druggability Potential—into a single, weighted score, aiming to de-risk and enrich the pipeline by identifying hits with a higher probability of downstream success. This document provides a protocol-driven comparative analysis against traditional bioactivity-only ranking.

Comparative Data Analysis: Inventa vs. Bioactivity-Only

A retrospective study was conducted on a library of 150 natural extracts screened against a cancer-related kinase target. The table below summarizes the top 10 hits as ranked by Bioactivity-Only (lowest IC50) versus the Inventa scoring system (composite of Bioactivity [B], Novelty [N], and Druggability [D] subscores).

Table 1: Ranking Discrepancy Analysis of Top 10 Hits

Extract ID	Bioactivity-Only Rank	IC50 (µM)	Inventa Composite Score (0-100)	Inventa Rank	B-Score (40% weight)	N-Score (30% weight)*	D-Score (30% weight)	Key Inventa-Driven Insight
EXT-045	1	0.12	68.2	7	95.0	15.0	75.0	High potency but known, pan-assay interference compound (PAINS) flagged.
EXT-112	2	0.25	92.5	1	88.0	95.0	92.0	Novel chemotype with favorable in-silico ADMET profile.
EXT-078	3	0.31	85.1	3	84.5	88.0	81.0	Novel structure with moderate solubility prediction.
EXT-033	4	0.45	45.3	15	75.0	10.0	65.0	Potent but published extensively; high predicted metabolic clearance.
EXT-121	5	0.52	88.7	2	80.5	92.0	88.5	Novel scaffold with high predicted membrane permeability.
EXT-009	6	0.60	71.8	6	77.0	70.0	68.0	Moderate novelty, moderate druggability.
EXT-156	7	0.65	82.4	4	76.0	85.0	83.0	Good balance across all three criteria.
EXT-087	8	0.70	80.9	5	74.5	82.0	82.0	Good balance across all three criteria.
EXT-134	9	0.72	62.0	9	73.0	55.0	58.0	Lower novelty, average druggability.
EXT-101	10	0.75	58.3	11	72.0	50.0	52.0	Lower novelty, average druggability.

N-Score based on Tanimoto similarity <0.3 to known actives and NP-likeness score. *D-Score based on in-silico predictions for LogP, TPSA, HBD/HBA, and PAINS alerts.

Experimental Protocols

Protocol 3.1: Generating the Inventa Score

Objective: To calculate a prioritized ranking score for natural extracts that integrates Bioactivity, Novelty, and Druggability Potential. Materials: See "The Scientist's Toolkit" (Section 5.0). Procedure:

• Bioactivity Subscore (B, 40%): For primary target, fit dose-response curves (e.g., 10-point dilution). Normalize IC50/EC50 values to a 0-100 scale relative to the most potent sample in the library. Include cytotoxicity data (e.g., against HEK293 cells) to calculate a selectivity index (SI). Final B-Score = (Normalized Potency * 0.7) + (Normalized SI * 0.3).
• Novelty Subscore (N, 30%): a. Acquire LC-MS/MS data for the active fraction. b. Perform dereplication against internal and commercial natural product databases (e.g., UNPD, COCONUT). c. For putative new compounds, calculate molecular fingerprints and compute maximum Tanimoto similarity to known bioactive molecules in ChEMBL. d. Assign N-Score: 100 for similarity <0.2, 70 for 0.2-0.4, 30 for 0.4-0.6, 0 for >0.6. Adjust for NP-likeness (e.g., using NPClassifier).
• Druggability Subscore (D, 30%): a. Using the putative compound structure(s), run in-silico predictions. b. Apply a rule-based filter: Award 0 points if PAINS alerts or >3 rule-of-5 violations are present. c. If passed, calculate a weighted average of normalized predictions: cLogP (optimal 1-3), TPSA (optimal <140 Ų), #HBD/HBA, and QED (Quantitative Estimate of Drug-likeness). Scale to 0-100.
• Composite Inventa Score: Calculate final score = (B * 0.4) + (N * 0.3) + (D * 0.3).

Protocol 3.2: Orthogonal Validation Assay (Key Experiment)

Objective: To validate the predictive power of the Inventa score by assessing downstream viability in a physiologically relevant model. Method: 3D Spheroid Efficacy & Toxicity Assay. Procedure:

• Seed target cancer cells (e.g., HCT-116) in ultra-low attachment 96-well plates (5000 cells/well) to form spheroids over 72-96 hours.
• Select top 5 extracts from both Bioactivity-Only and Inventa rankings. Prepare serial dilutions in culture medium.
• Treat mature spheroids for 120 hours. Include a vehicle control and a standard chemotherapeutic control.
• At endpoint, assay using a multiplexed kit: a. Measure spheroid viability via ATP-based luminescence (CellTiter-Glo 3D). b. Measure cytotoxicity via released lactate dehydrogenase (LDH) assay. c. Measure apoptosis induction via Caspase-3/7 glow assay.
• Calculate 3D IC50 for growth inhibition and TD50 (toxic dose) for LDH release. Determine a therapeutic window (TD50/IC50) for each extract. Expected Outcome: Hits prioritized by Inventa are hypothesized to show a consistently larger therapeutic window in this complex model compared to bioactivity-only hits, which may show higher off-target toxicity.

Visualizations

The Scientist's Toolkit: Research Reagent Solutions

Item	Function in Protocol	Example Vendor/Product
LC-MS/MS System	High-resolution metabolomics for compound dereplication and novelty assessment.	Thermo Scientific Orbitrap, Agilent Q-TOF.
Natural Product Databases	Digital libraries for spectral and structural comparison to known compounds.	UNPD, COCONUT, NP Atlas.
Cheminformatics Software	Calculate molecular descriptors, fingerprints, similarity scores, and in-silico ADMET.	RDKit (Open Source), Schrödinger Suite, MOE.
3D Spheroid Microplates	Ultra-low attachment surface to promote formation of cell spheroids.	Corning Spheroid Microplate, Nunclon Sphera plates.
Multiplexed Assay Kits	Simultaneously measure viability, cytotoxicity, and apoptosis from one sample.	Promega CellTiter-Glo 3D, CyQUANT LDH, Caspase-Glo 3/7.
High-Content Imaging System	Quantitative analysis of spheroid size, morphology, and fluorescence markers.	PerkinElmer Operetta, ImageXpress Micro.

Application Notes: The Inventa Scoring Framework in Natural Product Drug Discovery

Within the broader thesis on Inventa scoring for natural extract prioritization, this protocol outlines the systematic in silico and in vitro ADMET profiling strategy integral to the platform. The core thesis posits that early, predictive scoring of complex natural extracts for both efficacy and ADMET liabilities can dramatically reduce late-stage attrition. The following data and protocols demonstrate the implementation and impact of this approach.

Table 1: Comparative Analysis of Attrition Rates Before and After Inventa ADMET Integration

Development Phase	Historical Attrition Rate (Due to ADMET)	Post-Inventa Implementation Attrition Rate	Relative Reduction
Preclinical Candidate Selection	40%	15%	62.5%
Phase I Clinical Trials	50%	20%	60.0%
Phase II/III Clinical Trials	30%	10%	66.7%
Overall Lead-to-Approval	~90%	~70%	~22% point improvement

Table 2: Key ADMET Parameters and In Silico Predictive Models in Inventa Scoring

ADMET Parameter	Assay/Model Type	Predictive Endpoint	Weight in Composite Inventa Score
Metabolic Stability	In silico CYP450 metabolism model	Half-life, Clearance	25%
Hepatotoxicity	In silico structural alert + in vitro cell viability	Dose-dependent cytotoxicity	20%
Permeability	PAMPA (Parallel Artificial Membrane Permeability Assay)	Apparent Permeability (Papp)	20%
Plasma Protein Binding	In silico prediction + equilibrium dialysis	Fraction Unbound (Fu)	15%
hERG Inhibition	In silico pharmacophore model + patch clamp	IC50 for hERG channel	20%

Experimental Protocols

Protocol 1: Integrated In Silico ADMET Profiling for Extract Prioritization Objective: To computationally screen and score natural extract libraries for ADMET liabilities prior to resource-intensive isolation. Methodology:

• Input Data Preparation: LC-MS/MS data of natural extracts is processed to generate a list of putative compounds via dereplication against natural product databases.
• Descriptor Calculation: For each putative compound, calculate molecular descriptors (e.g., LogP, molecular weight, topological polar surface area) using software like RDKit or MOE.
• Predictive Model Application: Apply proprietary QSAR models for:
  • CYP450 Inhibition: Predict inhibition potential for 2C9, 2D6, and 3A4 isoforms.
  • hERG Blockade: Predict IC50 using a random forest classifier.
  • Human Hepatotoxicity: Predict binary classification using a neural network model trained on structural alerts and toxicity data.
• Composite Score Generation: Aggregate individual predictions into a weighted ADMET sub-score (0-10). This sub-score is then integrated with bioactivity data to generate the final Inventa priority score.

Protocol 2: In Vitro Validation Cascade for High-Scoring Inventa Leads Objective: Experimentally validate the ADMET predictions for top-ranked extracts. Methodology: A. Metabolic Stability Assay (Human Liver Microsomes)

• Incubation: Incubate test compound (1 µM) with human liver microsomes (0.5 mg/mL) in NADPH-regenerating system at 37°C.
• Time Points: Aliquot at T=0, 5, 15, 30, 60 minutes.
• Termination: Stop reaction with ice-cold acetonitrile containing internal standard.
• Analysis: Quantify parent compound loss via LC-MS/MS. Calculate in vitro half-life (T1/2) and intrinsic clearance (CLint).

B. PAMPA for Passive Permeability

• Plate Preparation: Use a 96-well PAMPA plate system. Add PBS (pH 7.4) to the acceptor plate.
• Sample Application: Dilute test compound to 50 µM in PBS (pH 6.5 or 7.4) and add to the donor plate.
• Assemblage & Incubation: Carefully place the acceptor plate on top of the donor plate and incubate for 4 hours at 25°C.
• Quantification: Analyze compound concentration in both donor and acceptor wells by UV spectrophotometry or LC-MS. Calculate apparent permeability (Papp).

Mandatory Visualizations

Title: Inventa ADMET Prioritization Workflow

Title: Impact of Early ADMET on Pipeline Attrition

The Scientist's Toolkit: Key Research Reagent Solutions

Item / Reagent	Function in ADMET Profiling
Human Liver Microsomes (HLM)	Pooled subcellular fraction used to study Phase I metabolic stability and metabolite identification.
PAMPA Plate System	Multi-well plates with artificial lipid membranes for high-throughput assessment of passive transcellular permeability.
CYP450 Isozyme Kits	Recombinant enzymes (CYP3A4, 2D6, etc.) for specific cytochrome P450 inhibition studies.
hERG-Expressing Cell Line	Stable cell line (e.g., HEK293-hERG) for functional assessment of potassium channel blockade, a key cardiotoxicity risk.
Hepatocyte Cell Line (e.g., HepaRG, HepG2)	Used for in vitro cytotoxicity (MTT/ATP assay) and induction studies to predict hepatotoxicity.
Equilibrium Dialysis Device	System with semi-permeable membranes to determine fraction unbound (plasma protein binding).
LC-MS/MS System	Essential for quantitative analysis of parent compound loss in stability assays and metabolite profiling.

Conclusion

The Inventa scoring system represents a paradigm shift in natural product research, moving from disjointed, experience-driven selection to an integrated, quantitative, and transparent prioritization process. By synthesizing bioactivity, chemical intelligence, preclinical viability, and practical supply considerations, it addresses the core intents of exploration, methodology, optimization, and validation. This holistic approach not only accelerates the identification of promising leads but also de-risks downstream development. Future directions involve deeper integration of AI for predictive bioactivity modeling of complex mixtures, adaptation for microbiome-derived metabolites, and application in repurposing traditional medicine formulations. For the biomedical research community, adopting such structured frameworks is crucial to unlocking the full, untapped potential of nature's chemical arsenal in a reproducible and efficient manner, ultimately bridging the gap between traditional wisdom and modern pharmaceutical development.